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1. SUMMARY 
In spite of the progress made in deciphering regulatory networks of cancer cells on the 
molecular level, the interaction of tumour cells with their stroma has not been adequately 
analyzed.  
 
Earlier, we have addressed the hypothesis that the murine embryonic microenvironment can 
induce the differentiation of human tumour cells. To examine such interactions, human 
leukaemic AML cells were injected into pre-implantation murine blastocysts at embryonic day 
3.5 of gestation. Analysis of developing mice revealed the presence of human AML cells in 
chimaeric embryos and adults and the appearance of haematopoietic differentiation markers 
on progeny of injected human AML cells. This finding strengthens the notion that the 
embryonic microenvironment is capable of regulating the proliferation and differentiation of 
leukaemic AML cells. 
 
Based on these results, I embarked to analyse the consequences of stromal environment-
induced changes in human AML cells upon in vitro coculture with selected haematopoietic 
stromal cell lines in terms of changes in differentiation and proliferation properties of AML 
cells. For this purpose, established human AML cell lines were cocultured on a variety of 
mitotically inactivated stromal cell lines derived from different murine embryonic/foetal 
haematopoietic sites such as yolk sac, aorta-gonad-mesonephros (AGM) region and foetal 
liver. To score for coculture-induced changes, I compared the morphology, histo-chemical 
properties, immunophenotype, proliferation rate, and gene expression profile in cocultured 
and non-cocultured AML cells. 
 
Results show that, upon coculture of Kasumi-1 cells- a cell line established from a FAB class 
M2 patient - with AGM-derived DAS 104-4, but not with other stromal cell lines, Kasumi-1 
AML cells exibit decreased proliferation and colony formation capabilities and acquire 
differentiated morphologies. Along this line, coculturing of Kasumi-1 cells resulted in the up-
regulation of the myelo-monocytic lineage cell surface markers CD11b and CD14. Coculture 
also resulted in increase in lysosomal marker CD68, a hallmark of myeloid differentiation. 
Interestingly, apart from cell lines, coculture on DAS 104-4 stroma was also efficient in 
inducing myeloid differentiation of patient derived primary M2-AML cells. Moreover, 
cocultivation of KG-1 cell line on DAS 104-4 showed activation of β-globin transcription and 
up-regulation of Glycophorin A on its surface, which indicate DAS 104-4 coculture-induced 
erythroid differentiation of KG-1 cells. 
 
Analysis of the proliferation rate of Kasumi-1 cells using the CFSE retention assay revealed 
that upon cocultivation on DAS 104-4, but not on NIH 3T3 cells, there is a decrease both in 
the proliferation rate and in the frequency of colony forming cells in clonogenic methyl 
cellulose cultures. Cell cycle analysis revealed the coculture-induced accumulation of G1-G0 
stage cells. 
 
Gene-expression analysis by quantitative RT-PCR revealed a substantial decrease in the 
amount of AML1 and AML1-ETO fusion transcripts in parallel with an increase in p16, p21, 
C/EBPα and PU.1 transcription levels. Interestingly, AML1-ETO transcription down-
regulation of AML cells needs direct contact with DAS 104-4 cells. 
 
Knocking down AML1-ETO expression by siRNA strategy led to reduction in proliferation and 
depletion of colony forming cells in Kasumi1 cell population. siRNA-mediated AML1-ETO 
knock-down Kasumi-1 cells showed increased susceptibility to stroma-induced myeloid 
differentiation. However, on its own, AML1-ETO down-regulation was not sufficient to induce 
myeloid differentiation. This indicates that AML1-ETO down-regulation may have an active 
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role on the coculture-induced effect but in addition to AML1-ETO down-regulation, further 
stimuli are required for the coculture-induced myeloid differentiation in the AML cells. 
 
In summary, in the present study I established and characterised a coculture-based in vitro 
system, which is capable of reducing the proliferation while inducing differentiation of human 
AML cells. The concept emerging from the studies indicates that the stroma environment can 
affect leukaemic cell proliferation and differentiation in contact-dependent and CD44 
activation-independent manner. Furthermore, this study emphasizes the role of AML1-ETO 
in AML and indicates that AML1-ETO down-regulation is involved in the stroma-induced 
differentiation of Kasumi-1 cells. The result described here encourages further investigation 
into the mechanistic details of molecular and cellular interactions between the leukaemic 
cells and their stroma, which in turn may lead to the identification of new paradigms for a 
knowledge-based control and reprogramming of leukaemic cells. 
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2. ZUSAMMENFASSUNG 
Neuere Erkenntnisse in der Tumorforschung belegen, dass die Mikroumgebung neben 
anderen Faktoren eine bedeutende Komponente im komplexen regulatorischen Netzwerk 
von Tumorzellen darstellt. Doch obwohl in den letzten Jahren große Fortschritte hinsichtlich 
des molekularen Verständnisses der Tumorzell-Regulation gemacht wurden, wurden die 
Interaktionen zwischen Tumor- und Stromazellen bislang nur unzureichend analysiert. 
 
In früheren Untersuchungen stellten wir die Hypothese auf, dass die murine embryonale 
Mikroumgebung humane Tumorzellen zur Differenzierung anregen kann. Um diese 
Wechselwirkungen zu untersuchen, wurden humane AML-Zellen in murine Blastozysten 
injiziert und diese in scheinträchtige Ammentiere implantiert. Humane Zellen konnten sowohl 
in den sich entwickelnden Embryonen als auch in daraus hervorgegangenen adulten Tieren 
nachgewiesen werden. Außerdem  exprimierten die Nachkommen der injizierten AML-Zellen 
hämatopoetische Differenzierungsmarker. Diese Beobachtungen unterstützen die Hypothese, 
dass die embryonale Mikroumgebung in der Lage ist, die Proliferation und Differenzierung 
humaner Leukämiezellen zu beeinflussen. 
 
Aufbauend auf diesen Ergebnissen habe ich damit begonnen, die Stroma-vermittelten 
Veränderungen in humanen AML-Zellen hinsichtlich ihres Proliferations- und 
Differenzierungsverhaltens in einem in vitro Kokultur-System zu untersuchen. Hierzu wurden 
etablierte humane AML-Zelllinien mit verschiedenen murinen Stromazelllinien kokultiviert, die 
embryonalen hämatopoetisch aktiven Geweben (Dottersack, Aorta-Gonaden-Mesonephros-
Region, foetale Leber) entstammen. Anschließend wurden verschiedene Parameter, wie 
Morphology, Histochemie, Immunphänotyp, Proliferationsrate und Expression bestimmter 
Gene, kokultivierter und nicht kokultivierter AML-Zellen verglichen. 
 
Die Ergebnisse zeigen für Kasumi-1 Zellen, eine etablierte humane Leukämie-Zelllinie vom 
AML FAB-Typ M2, dass die Kokultur mit DAS 104-4, einer murinen Sromazelllinie, die der 
AGM-Region entstammt, eine Reduzierung der Proliferations- und Koloniebildungs-Fähigkeit 
hervorruft und sich die Morphologie der AML-Zellen in Richtung eines differenzierteren 
Zelltyps ändert. 
 
Übereinstimmend damit können nach Kokultur die myelo-monozytären 
Differenzierungsmarker CD11b und CD14 auf der Oberfläche der Kasumi-1-Zellen 
nachgewiesen werden. Die Kokultur führte ebenfalls zu einer Zunahme des lysosomalen 
Markers CD68, der ebenfalls eine myeloide Differenzierung kennzeichnet. Bemerkenswert 
ist, dass DAS 104-4 Stromazellen in der Lage sind, myeloide Differenzierung auch in 
primären M2-AML-Zellen aus einem leukämischen Patienten zu induzieren. Außerdem 
wurde in KG-1 AML Zellen nach Kokultur mit DAS 104-4 eine Aktivierung der  -Globin-
Transkription und eine verstärkte Glycophorin-A-Expression beobachtet, was auf eine 
Differenzierung der KG-1-Zellen in Richtung erythroide Linie hindeutet. 
Untersuchungen zur Proliferationsfähigkeit von Kasumi-1-Zellen mittels CFSE-Retentions-
Messungen ergaben, dass nach Kokultur mit DAS 104-4 - nicht aber mit NIH 3T3-
Kontrollzellen - die Zellteilungsrate vermindert ist. Gleiches gilt für die Koloniebildungs-
Kapazität in Methylzellulose-Kulturen. Zellzyklus-Analysen zeigen eine kokulturinduzierte 
Akkumulation der AML-Zellen im G1-G0  Stadium. 
 
Genexpressionsanalysen mit Hilfe quantitativer RT-PCR verweisen auf eine deutlich 
herabgesetzte Transkription von AML1 und dem AML1-ETO-Fusionsgen, verbunden mit 
einem Anstieg  der p16-, p21-, C/EBP   und PU.1-Transkription. Interessanterweise ist die 
Abnahme von AML1-ETO Transkripten abhängig vom direkten Zellkontakt zwischen AML- 
und DAS 104-4-Zellen. 
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Wird die AML1-ETO-Expression nach Einsatz spezifischer siRNA herunter reguliert, führt 
dies zu einer verminderten Proliferation und zur Depletion koloniebildender Zellen innerhalb 
der Kasumi-1-Population. Außerdem bewirkt der siRNA-vermittelte knockdown von AML1-
ETO eine höhere Empfänglichkeit der Kasumi-1-Zellen für die Stroma-induzierte myeloide 
Differenzierung. Die Verringerung von AML1-ETO Transkripten allein hat allerdings keinen 
differenzierenden Effekt. Diese Beobachtungen sprechen dafür, dass AML1-ETO zwar aktiv 
an der kokultur-vermittelten Reaktion beteiligt ist, dass aber zusätzliche Stimuli nötig sind, 
um myeloide Differenzierung in den AML-Zellen auszulösen. 
 
Zusammenfassend lässt sich feststellen, dass in der vorliegenden Arbeit ein Kokultur-
basiertes in vitro System entwickelt und charakterisiert wurde, das in der Lage ist, die 
Proliferationsfähigkeit von humanen AML-Zellen zu senken und ihre Differenzierung in die 
myeloide Linie zu induzieren. Aus den dargestellten Ergebnissen lässt sich schließen, dass 
das umgebende embryonale Stroma die Proliferation und Differenzierung leukämischer 
Zellen beeinflussen kann. Die zugrunde liegenden Mechanismen sind abhängig vom direkten 
Kontakt zwischen Stroma- und AML-Zellen. Eine CD44-Aktivierung konnte nicht beobachtet 
werden. 
 
Weiterhin liefert die vorliegende Arbeit Hinweise darauf, dass die Verminderung der AML1-
ETO-Transkription ein bedeutendes, jedoch nicht das allein auslösende, Ereignis der stroma-
induzierten Differenzierung von Kasumi-1-Zellen darstellt. Die hier beschriebenen Resultate 
regen zu weiterführenden Untersuchungen an, die Aufschluss über zelluläre und molekulare 
Details der Interaktionen zwischen Leukämischen und Stromazellen geben sollen. Neue 
Erkenntnisse über die beteiligten Mechanismen könnten den Ansatz bieten, der es erlaubt, 
leukämische Zellen aktiv zu kontrollieren und zu reprogrammieren. 
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3 INTRODUCTION 
 
3.1 Acute myeloid leukaemia – The disease 
 
Acute Myeloid Leukaemia (AML) is a clonal myeloproliferative disease, characterized by an 
uncontrolled proliferation and block in differentiation of myeloid committed blood cells in the 
bone marrow (BM) (Jinnai, 1995). The diagnosis of AML is made when over 30% of myeloid 
blast cells are observed in the BM of the patient. The excessive amount of myeloid blast cells 
in the bone marrow competes and interferes with the normal haematopoiesis. This results in 
anemia, granulocytopenia and thrombocytopenia leading to symptoms such as fatigue, 
dizziness, bleeding and infections. AML occurs as a result of genetic changes often evident 
as cytogenetic changes, which can be detected in the majority of patient samples. The type 
of cytogenetic abnormality is considered the most powerful independent risk factor for 
outcome and the various genetic changes can be classified in a favourable, intermediate or 
poor risk groups (Grimwade et al., 1998). 
 
AML can also be classified according to its morphology using the French-American-British 
(FAB) classification (Table 1). Recently, a more clinical relevant classification has been 
proposed by the World Health Organization (WHO) (Table 2). This classification stratifies 
hematologic malignancies according to a combination of morphology, immunophenotype, 
genetic features and clinical syndromes (Harris et al., 1999). According to the WHO 
classification, the diagnosis of AML is made when over 20% instead of 30% blast cells are 
present in the Bone marrow. 
  
The incidence of AML is 2.4/100,000 people per year in the United States and it occurs 
mainly in elderly patients with a median age of onset of 63-65 years (Leith et al., 1995). AML 
patients under 50 years of age, treated with curative intent chemotherapy, have complete 
remission (CR) rates that average 70% with a median relapse free survival (RFS) of nearly 2 
years (Lowenberg et al., 1999).  In contrast, in the elderly AML patients, CR rates only 
average 50% with a median RFS in these patients of only 9 to 12 months (Bishop et al., 1996; 
Mayer et al., 1994; Rowe et al., 1995; Taylor et al., 1995). The poorer outcome of AML in the 
elderly patients may result from adverse cytogenetics, expression of multi-drug resistance 
proteins, reduced patient tolerance to chemotherapy or a combination of these factors (Leith 
et al., 1995). However, despite age or biological differences, most patients eventually relapse 
and die of the disease. 
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Table 1. FAB classification of AML depending on the maturation status of 
AML blast (Casasnovas et al., 1998; Harris et al., 1999) 
French American British 
(FAB) Classification Morphology 
M0 Acute Myeloblastic Leukaemia with minimal differentiation 
M1 Acute Myeloblastic Leukaemia without maturation 
M2 Acute Myeloblastic Leukaemia with maturation 
M3 Acute Promyelocytic Leukaemia 
M4 Acute Myelomonocytic Leukaemia 
M4eo Myelomonocytic Leukaemia with abnormal eosinophils 
M5a Acute Monoblastic Leukaemia 
M5b Acute Monocytic Leukaemia 
M6 Acute Erythroleukaemia 
M7 Acute Megakaryocytic leukaemia 
 
 
 
 
 
Table 2. WHO classification of AML cells, depending on morphology, immuno-
phenotype, genetic features and clinical syndromes (Harris et al., 1999) 
WHO classification Definition 
I AML with recurrent cytogenetic translocations 
II AML with myelodyplasia-related features 
III Therapy-related AML and MDS 
IV AML not otherwise categorized 
 
 
 
 
3.2 Acute Myeloid leukaemia: The biology 
 
AML is characterized by an uncontrolled proliferation and accumulation of myeloid blast cells 
in the bone marrow, blood and other organs of patients. It is thought that the disease is 
sustained by a small subset of cells capable of extensive self-renewal and proliferation, 
which gives rise to the more mature myeloid blast cells (Blair et al., 1998; Bonnet and Dick, 
1997; Sutherland et al., 1996). These cells, uniquely capable of sustaining the disease, are 
called AML stem cells. 
  
The haematopoietic system is a complex and tightly regulated and hierarchically structured 
cell system, in which pluripotent stem cells undergo proliferation and differentiation to 
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produce mature blood cells of the various lineages while maintaining a compartment of 
uncommitted cells. As mentioned above, AML occurs as a result of genetic changes. Such 
changes occur in a primitive haematopoietic cell type that gives rise to the malignant clone. 
Despite the lack of mature cells derived from the leukaemic clone in the majority of AML 
patients, there is considerable heterogeneity among the leukaemic blasts even within 
individual patients, particularly with respect to their capacity to proliferate and/or self-renew 
(Blair et al., 1998; Bonnet and Dick, 1997; Sutherland et al., 1996). This suggests that 
subsequent to the transformation and prior to the maturation arrest some differentiation of 
AML blasts occurs, which creates a hierarchy of AML progenitors just as seen in normal 
haematopoiesis (Figure 1). 
  
Over the years, several in vitro assays have been developed to detect normal 
haematopoietic progenitors. Lineage committed progenitor cells can be detected in vitro by 
the colony forming cell assay (CFU assay), in which haematopoietic cells are plated in semi-
solid media complemented with growth factors (GF) (Eaves CJ, 1999; Sutherland H.J., 1991). 
More primitive progenitors can be assayed in the long-term culture assay (LTC) (Hogge et al., 
1996). In this assay, cells are cultured for 5 to 8 weeks on murine stromal feeders producing 
human GFs and after 5 to 8 weeks, the cells are harvested and plated in semi-solid media 
upon which the LTC-initiating cell (LTC-IC) content can be determined. It is thought that the 
most primitive pluripotent stem cells can only be detected in vivo by multi-lineage 
engraftment in the non-obese diabetic severe combined immunodeficient (NOD/SCID) mice. 
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Figure 1. Presently accepted leukaemic stem cell model, which states that AML is a stem cell 
disease and can arise from normal haematopoietic stem cells or progenitor cells. These 
leukaemic stem cells give rise to leukaemic progenitors, which in turn lead to AML blast cells and 
depending on cytogenetics, they get blocked in different stages of differentiation (Bonnet and 
Dick, 1997; Dick, 2005; Dick and Lapidot, 2005; Hope et al., 2003; Hope et al., 2004). Figure is 
adapted from Bonnet et al., modified by Michael Dürr and eventually modified by me. 
 
3.2.1 Acute myeloid leukaemia and translocation t(8;21) 
AML is a clonal disorder resulting from an acquired somatic mutation in haematopoietic 
progenitor cells and it is characterized by an accumulation of immature myeloid cells in the 
bone marrow, which are arrested in different stages of maturation. Frequently, in AML, the 
acquired mutation is the consequence of a balanced reciprocal chromosomal translocation, 
which disrupts genes residing in the breakpoint regions of the translocation by generating 
fusion genes (Look, 1997; Lowenberg et al., 1999). The genes located at these breakpoints 
often encode transcription factors, which are master regulators of haematopoietic cell 
differentiation, apoptosis or proliferation (Tenen et al., 1997). 
 
Despite the heterogeneity of AML, the identification of recurring chromosomal 
rearrangements and the resulting molecular abnormalities have identified distinct subgroups 
of patients with predictable clinical features and therapeutic responses (Downing, 1999). The 
most frequent cytogenetic abnormalities in AML, accounting for approximately 40% of all 
AMLs, are the translocations t(8;21), t(15;17), inv(16) and t(9;11), encoding for the AML1-
ETO, PML-RARα, CBFβ-SMMHC and MLL-AF9 fusion proteins, respectively (Look, 1997). 
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AML1-ETO is associated with approximately 40% of AML cases with the M2 subtype 
according to the French-American-British (FAB) classification and represents one of the most 
frequent chromosomal translocation in AML (18-20%) (Look, 1997). t(8;21) is a balanced 
translocation between chromosomes 8 and 21 resulting at the molecular level in the fusion of 
the AML1 gene normally located on chromosome 21q22 with the ETO (Eight-Twenty-One) 
gene on chromosome 8q22 (Erickson et al., 1992; Nucifora et al., 1993). The wild type AML1 
gene encodes for the CBFβ2 protein, which is a physiological component of the core binding 
factor (CBF) family (Chang et al., 1993). AML1 appears to function as a transcriptional 
organizer necessary for the development of definitive haematopoietic stem cells (Carey, 
1998). In fact, CBF null mice die in utero in the absence of terminal haematopoietic 
differentiation (Okuda et al., 1998; Speck et al., 1999; Wang et al., 1996). Transcriptional 
function of AML1 is mediated through the core enhancer DNA sequence present in 
promoters and enhancers of a large number of haematopoietic specific genes (Mayer et al., 
1994). AML1 binds this sequence through the runt homology domain and its DNA binding 
affinity is increased by heterodimerization with CBFβ  (Ogawa, 1993). Finally, AML1 has 
been shown to co-operate with other transcription factors in activating a set of 
haematopoietic specific genes (Petrovick et al., 1998). ETO was unknown prior to its 
identification as the fusion partner of AML1 in t(8;21) (Erickson et al., 1992; Miyoshi et al., 
1993; Nisson et al., 1992). ETO is expressed as a nuclear phosphoprotein in brain and in 
CD34+ haematopoietic cells (Erickson et al., 1996). It contains four evolutionarily conserved 
regions, the so-called nervy homology regions (NHR) 1-4, which have been shown to make 
several contacts with co-repressors and histone deacetylases (Amann et al., 2001). Although 
ETO is a nuclear zinc-finger containing protein and thus might function as a transcriptional 
regulator, there is no experimental evidence to suggest that it can directly bind to DNA. In the 
translocation t(8;21), the DNA binding domain (runt domain) of AML1 is fused to nearly the 
complete ETO gene yielding a protein of 752 amino acids (Erickson et al., 1992; Miyoshi et 
al., 1991; Nisson et al., 1992). Several important regions of AML1 are lost, like the C-terminal 
transactivation domain, interaction sites for Groucho/TLE family of transcriptional co-
repressors and sin3 co-repressors, the nuclear targeting signal and a MAP kinase 
phosphorylation site (Licht, 2001). AML1-ETO sequesters the co-activator CBFβ  from wild 
type AML1 by binding CBFβ through the retained runt domain more efficiently (Tanaka et al., 
1998). Thus, AML1-ETO can bind to AML1 target genes instead of wild type AML1 (Meyers 
et al., 1993), and dominantly represses transcription of AML1 target genes by permanently 
tethering a repressor complex to AML1 responsive promoters through ETO (Gelmetti et al., 
1998; Lutterbach et al., 1998; Wang et al., 1998). The importance of disruption of wild type 
AML1 by AML1-ETO is shown by a similar phenotype in AML1 knock-out and AML1-ETO 
knock-in studies (Okuda et al., 1998; Yergeau et al., 1997). AML1-ETO blocks the 
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transactivation of wild type AML1 target genes important for myeloid differentiation, like the 
GM-CSF, c-fos (Harada et al., 2001; Hwang et al., 1999) or the TGFβ  signalling pathway 
(Jakubowiak et al., 2000). Furthermore, AML1-ETO disrupts the protein-protein interactions 
of AML1 with important myeloid transcription factors like C/EBPα (Pabst et al., 2001; 
Westendorf et al., 1998) or MEF-2 (Mao et al., 1999) and also represses transactivation 
through those transcription factors. Therefore, AML1-ETO might be responsible for the 
differentiation arrest in t(8;21). Along with that, several cellular and murine model systems 
have documented the ability of AML1-ETO to inhibit myeloid differentiation (Ahn et al., 1998; 
Burel et al., 2001; Kitabayashi et al., 1998; Kohzaki et al., 1999; Tanaka et al., 1995). 
 
It has recently been shown that AML1-ETO might also be responsible for the gain-of-function 
properties characterizing leukemogenesis. Expression of AML1-ETO in primary human 
CD34+ stem cells, the target cell affected in AML, results in a proliferative and survival 
advantage of leukaemic cells, which promotes their expansion (Mulloy et al., 2002). 
Introduction of the AML1-ETO cDNA into the AML1 locus by homologous recombination 
leads to embryonic lethality in heterozygous animals (Ohneda et al., 1998; Yergeau et al., 
1997). Culturing yolk sac cells of these mice, however, yields dysplastic monocytic colonies 
(Yergeau et al., 1997). In a similar AML1-ETO knock-in mouse study, aberrant 
myelomonocytic colonies are derived from foetal liver (Ohneda et al., 1998). 
 
In summary, despite the fact that AML1-ETO alone has not been shown to cause leukaemia 
(Rhoades et al., 2000; Yuan et al., 2001), these studies indicate that AML1-ETO encourages 
uncontrolled cell growth and might predispose to leukaemia.  
 
3.3 Cell cycle regulatory proteins and their role in cell proliferation 
and cell cycle arrest 
 
It is a universal process by which cells divide and participate to the growth and development 
of organisms. G1 phase is tightly regulated to coordinate normal cell division with cell growth, 
whereas replication of DNA during S phase is precisely ordered to prevent inadequate 
events that will lead to genomic instability and cancer. The cell cycle machinery, as such, is a 
highly coordinated process in which cyclins, cyclin-dependent kinases (CDKs) and their 
inhibitors (CDKIs) are differentially regulated (Gitig and Koff, 2000; Koepp et al., 1999; 
Matsushime et al., 1990; Muller et al., 1993; Sherr and Roberts, 2004). Each cyclin can 
associate with one or more of the CDK family and successive ways of cyclin/CDKs 
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complexes drive cells through the cell cycle, acting in G1 to initiate S phase and in G2 to 
initiate mitosis. While levels of CDKs remain constant through the cell cycle, expression of 
cyclins varies following periodic transcriptional or posttranscriptional regulations, so that each 
cyclin has a unique pattern of expression during the cell cycle. Since cyclin abundance is 
rate limiting, the different CDKs get activated upon binding to their specific cyclin partner 
provided that these subunits are available. During the G1 phase of the cell cycle, two classes 
of cyclins get successively activated: D type cyclins (cyclins D1, D2 and D3) (Steinman, 2002) 
and cyclin E (cyclins E1 and E2) (Koepp et al., 1999). These cyclins associate with their 
respective partners, CDK4 or CDK6 for cyclin D and CDK2 for cyclin E to induce their kinase 
activities (Bates et al., 1994; Meyerson and Harlow, 1994). Activated CDK4/CDK6 and CDK2 
are required for phosphorylation of the retino-blastoma protein (pRb), an event that leads to 
the release of Rb-E2F repressor complex and hence, to the induction of E2F-dependent 
genes and cell cycle progression (Bates et al., 1994). Cyclins D and CDK4/6 are responsible 
for the first phosphorylation of pRb, while cyclin E/CDK2 operates on both the second pRb 
phosphorylation and the control of S phase entry. The activity of G1 cyclin-CDK complexes is 
regulated, at least in part, by CDKIs, among which two members, p21 and p16 play specific 
roles. Evidence is accumulating that CDKIs are targets of extracellular and intracellular 
signals that regulate cell growth and differentiation (Harper et al., 1993; Nead et al., 1998; 
Nishitani et al., 1999; Steinman et al., 1994). The p21 inhibitor is known to be triggered by 
anti-proliferative and differentiation signals and as a mediator of p53-induced cell cycle arrest 
after DNA damage (Steinman et al., 1998). 
 
 
 
3.4 Response of AML cells to differentiation-inducing agents 
 
AML is a disease that is characterized by a block in the normal process of myeloid 
differentiation, thereby leading to the accumulation of immature cells termed blasts 
(Lowenberg et al., 1999; Tenen et al., 1997). The abnormal maturation in AML cells could 
result from disruption of the function of transcription factors, cytokine receptors and the cell 
cycle. In other words, leukaemic transformation might involve abnormalities of the 
transcription factors that normally regulate myeloid development in a stepwise fashion. 
 
AML treatment is based on intensive chemotherapy administered based on: a) induction 
treatment that aims to bring the patient into complete hematological remission, and b) 
treatment in remission that aims to eradicate residual disease and prevent AML relapse 
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(Lowenberg et al., 1999). Treatment in remission with intensive chemotherapy alone or in 
combination with stem cell transplantation is associated with a relatively high mortality 
(Bruserud et al., 2000; Lowenberg et al., 1999). The use of a less aggressive therapy is 
therefore, highly desirable. One potential approach might be the induction of differentiation of 
leukaemic blasts turning them into non-dividing end cells. 
 
In an experimental setting, AML cells can be induced to differentiate with a variety of agents. 
In 1978, Sachs and co-workers demonstrated that mouse cells undergo differentiation in the 
presence of IL6 (Sachs, 1978). Later it was reported that the vitamin A metabolite, retinoic 
acid (RA), could induce differentiation in the betty-60 cell line (Breitman et al., 1980), with the 
effect mediated through the retinoic acid receptor (RAR) (Collins et al., 1990). The 
application of differentiation therapy with All Trans Retinoic Acid (ATRA) is now regarded as 
the choice for treatment of M3-AML (He et al., 1999; Kogan and Bishop, 1999). There are 
currently a large number of prototypes and second-generation agents that are capable of 
inducing differentiation in either myeloid or lymphoid cell lines (Hozumi, 1998; Tallman, 1996), 
many of which have been used in clinical situations, albeit in only few cases, often this is in 
combination with other factors (Table 3a & 3b). 
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Table 3a. Differentiation inducers of AML  
Direction of 
differentiation 
Soluble 
mediators Detection of differentiation in native AML blasts 
SCF or IL-3 
Induction of CD15 expression and promyelocyte-
myelocyte morphology in CD34+ AML-M1/M2 blasts 
(Matsushima et al., 2001). 
IL-3, G-CSF or 
GM-CSF 
Differentiation into myelocyte- and metamyelocyte-like 
leukaemic cells with disappearance of CD34 and HLA-DR 
expression for a subset of patients (Ikeda et al., 1993). 
SCF 
Enhanced differentiation when G-CSF was combined with 
retinoic acid decreased colony formation in clonogenic 
assay; these effects were caused by single agents and/or 
by combinations of mediators.(Ferrero et al., 1992; Santini 
et al., 1991) 
Neutrophil 
IFN- , Vit-D3, or 
Retinoic acid 
Increased proportions of mature granulocytes for some 
patients (Greenberg et al., 1990). 
Eosinophil IL-5 
Induction of either pure or mixed leukaemic eosinophilic 
colonies, no correlation with FAB classification IL-5(Ema et 
al., 1990; Motoji et al., 1990; Motoji et al., 1995). 
SCF 
Differentiation into cells with segmented nuclei and 
basophilic/metachromatic granules for a small minority of 
patients (Matsushima et al., 2001). 
Basophil 
IFN-γ, TNF-α 
Increased membrane expression of the monocyte marker 
CD14 in subsets of patients; effects were caused by single 
agents or combinations of mediators (Howell et al., 1990). 
Vit-D3, or retinoic 
acid TNF-α 
Induction of monocytic morphology with increased 
phagocytic capacity and expression of CD11b and CD14 
(Masciulli et al., 1995). 
IL-3, GM-CSF, G-
CSF, or M-CSF 
Induction of a macrophage-like morphology and 
expression of CD13, CD14, and HLA-class II in a minority 
of patients (Salem et al., 1989). 
Monocyte 
SCF, Leukaemia 
inhibitory factor 
Monocyte differentiation in the M1 AML cell line (Brasel et 
al., 1995). 
Megakaryocyte Thrombopoietin + IL-3 or SCF 
Increased expression of platelet-specific antigens in the M-
O7e AML cell line (Briggs et al., 2001). 
Erythroid Erythropoietin Further erythroid differentiation for patients with erythroleukaemia (Salem et al., 1989). 
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Table 3b. Candidate drugs for differentiation induction (Tallman, 1996) 
Cytarabine, daunorubicin, 6-thioguanine 
Combinations  of  cytosine  arabinoside thioguanine  
plus  retinoic  acid  
Cytotoxic drugs 
Hexamethylene or dimethylformamide 
Histone deacetylase inhibitors 
Butyrates Altered Histone Acetylation 
Monosaccharide butyrate derivatives 
Methylprednisolone High-Dose Methylprednisolone 
Metal Chelators Dithizone 
ATRA and Vitamin D3 Analogs ATRA and Vitamin D3 Analogs 
    
 
 
 
 
3.4.1 Targeting AML with antibodies 
 
Going further ahead in differentiation induction, antibody-based therapy for acute leukaemia 
has evolved as a possible means of decreasing both relapse rates and mortality (Ruffner and 
Matthews, 2000). Over the past 25 years, monoclonal antibodies have been evaluated as 
anti-leukaemic therapy both in unmodified forms and as immuno-conjugates labelled with 
either radioactive or cytotoxic moieties. For example, anti-GM-CSF antibody (Bouabdallah et 
al., 1998), humanized anti-CD33 antibody (HuM-195) (Caron et al., 1998) or 131I-labelled anti-
CD33 (p67) (Sievers et al., 1999) and anti-CD45 antibody (Sievers, 2000). Most monoclonal 
antibody targeting approaches have been directed against normal haematopoietic cell 
surface antigens that are also expressed by leukaemic blast cells (Sievers, 2000). 
 
Recently, it has been shown that the ligation of the CD44 surface antigen by specific anti-
CD44 monoclonal antibodies or with its natural ligand, hyaluronan, can induce myeloid 
differentiation in AML M1 to AML M5 subtypes (Charrad et al., 1999). It was reported 
previously that one can induce differentiation upon CD44 ligation with the anti-CD44 antibody, 
A3D8, in the AML cell lines HL60, U937, THp-1, KG-1a and NB4 (Charrad et al., 1999; Zada 
et al., 2003). Furthermore, it was shown that in vivo administration of CD44 activating 
antibody to leukaemia progenitor-transplanted NOD-SCID mouse, showed significantly less 
leukaemic repopulation (Jin et al., 2006). This shows a new development for targeted 
differentiation therapy in AML. 
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3.5 Tumour cells and microenvironment background 
 
Based on observations from early last century that some cancer types are prevalent in 
certain families, researchers began to look for genetic alterations that might underlie cancer 
pathogenesis. Over the following decades, enormous advances were made in identifying the 
molecular determinants of tumourigenesis. Tumour development became recognized as a 
multi-step process during which cancer cells accumulate multiple and consecutive genetic 
alterations (Mueller and Fusenig, 2004). These cancer-, cell-, and genome-centred models 
have led to the identification and characterization of many oncogenes and tumour-
suppressor genes, which in turn yielded detailed information on the molecular basis of 
tumour development. However, they have largely ignored the heterogeneous and structurally 
complex nature of the tissue, or “organ”, called the tumour. The English surgeon Stephen 
Paget back in 1889, compared tumour cells with the seed of plants, in that they are both 
“carried in all directions; but they can only live and grow if they fall on congenial soil”. 
Similarly, he argued that metastatic cells must thrive only where conditions are in some way 
favourable. The molecular determinants of the “seed” are still much better understood than 
those of the “soil”. It is only recently that tumour progression has been recognized as the 
product of an evolving crosstalk between different cell types within the tumour and its 
surrounding supporting tissue or tumour microenvironment. Over the past decade, it has 
become increasingly apparent that the complex interplay between different cell types and the 
microenvironment is critical for maintaining normal balanced tissue homeostasis. As a 
consequence, in tumour tissue, the microenvironment will also profoundly influence many 
steps of tumour development and progression. 
 
In vivo, the tumour is a complex ecosystem comprising the genetically altered neoplastic 
cells and the tumour stroma, a framework of different connective tissue cells with 
extracellular matrix (ECM) and the embedded vasculature. Although changes in the 
cellularity and ECM composition of the tumour stroma had been previously noticed (Wills, 
1967), this connective tissue component of epithelial malignancies was considered mainly as 
a passive supporting and nourishing system for the cancer cells. Concomitantly with the 
increasing interest in tumour angiogenesis and the recognition of its essential role for tumour 
progression and as a new target for tumour therapy, a new view of the significance of the 
stromal compartment in tumour biology has emerged. With the recognition of the fact that 
tumours are composed of many cell types and cannot exist in isolation, increasing 
experimental evidence emphasized the importance of the microenvironment for tumour 
development and progression. These data indicate that the genetic alterations in the tumour 
cells themselves are not sufficient to generate a malignant tumour but that a permissive 
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stromal environment is needed as well. Comparison of the connective tissue of normal 
organs, which is able to maintain normal tissue homeostasis, with the tumour stroma 
revealed a disrupted balance in the epithelial-stromal interactions in both composition of the 
ECM and the functional state of the stromal cells (Coussens et al., 2001; Tlsty, 2001; van 
den Hooff, 1988). These alterations seem, indeed, to be crucial for tumour growth, invasion, 
and metastasis (Fidler, 1990; Morikawa et al., 1988). 
 
Recent in vitro studies indicate that both cell composition and functional abnormalities of the 
haematopoietic microenvironment are present in a proportion of patients with myeloid 
leukaemia, both chronic myeloid leukaemia (CML) and acute myeloid leukaemia. Cell 
composition abnormalities have been primarily observed in a subset of patients with AML; 
these abnormalities include reduced numbers of fibroblast progenitors and, in some cases, 
reduced numbers of macrophages and adipocytes. In terms of function, it has been shown 
that the marrow stromal cells, from a significant number of both CML and AML patients 
possess a deficient haematopoietic supportive capacity in vitro. However, it is not clear 
whether the abnormalities in the haematopoietic microenvironment are secondary to myeloid 
leukaemia or if they precede clinical CML/AML. 
 
Complex interactions between interspecies stroma and cancer have been reported in the 
context of human AML cell lines. Upon cocultivation, murine stromal MS-5 cells prevent 
serum deprivation-induced apoptosis and inhibit ara-C-induced apoptosis in HL-60 cells. This 
effect was shown to be due to murine stroma-induced upregulation of BCL2 expression in 
the human AML cell line (Konopleva et al., 2002). 
 
 
 
3.5.1 Reprogramming of tumour in embryonic environment 
 
Brinster et al., (1976) reported that testicular teratocarcinoma cells transplanted into 
blastocysts can survive and contribute to the resulting embryos without leading to 
carcinogenesis (Brinster, 1974). Illmensee et al., (1976), further showed loss of malignant 
phenotype and germline transmission of blastocyst injected with teratocarcinoma cells 
(Illmensee and Mintz, 1976). The control of tumour formation is also highlighted by the 
observation that human mestastatic melanoma cells engrafted into the chick neural crest 
region acquire neural-crest-cell-like morphologies and populate into host peripheral 
structures (Kulesa et al., 2006). In addition, work form our lab showed that the murine 
embryonic microenvironment can induce the differentiation of human AML cells following 
blastocysts injection. Microinjection of human KG-1 myeloid leukaemia cells and primary 
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human acute myeloid leukaemia cells led to the generation of chimaeric embryos and adults 
without signs of tumour formation. Furthermore, analysis of chimaeric E12.5 embryos 
revealed that the progeny of human KG-1 cells activated erythroid-specific human globin and 
glycophorin A (CD235a) expression (Durr et al., 2003). In summary, the available data 
suggest that the embryonic microenvironment can reprogram human leukaemia cells to 
differentiate. 
 
3.6 Sites of embryonic and adult haematopoiesis and 
haematopoietic stroma 
 
The different cell lines used in this study are derived from different haematopoietic regions of 
embryos and adult mice. Therefore, the origin of the haematopoietic system is briefly 
discussed. Blood development in vertebrates occurs in two phases: The embryonic 
(“primitive”) phase and the definitive (“adult”) phase (Davidson and Zon, 2004) (Figure 2). 
These phases differ in the sites of blood cell production, also in the morphology of the 
produced cells and in the types of expressed genes. During the embryonic phase of 
haematopoiesis, the embryo is transiently provided with primitive blood cell types from the 
extra-embryonic yolk sac. During the definitive phase of haematopoiesis, the embryo is 
supplied with blood cells that originate from the intra-embryonic aorta-gonad-mesonephros 
(AGM) region. These definitive-type hematopoetic stem cells (HSCs) last for the entire 
lifetime. At each stage of development, different subsets of mature haematopoietic cells are 
generated. Definitive erythroid cells are small and enucleated in adult organisms, while 
primitive erythroid cells produced during embryonic yolk sac haematopoiesis are large and 
nucleated. Specific types of B cells and T cells are produced by progenitors in the foetal liver 
(Bonifer et al., 1998; Dzierzak et al., 1998). There are differences between embryonic/foetal 
and adult-type macrophages (Faust et al., 1997). The first extra-embryonic sites of 
haematopoiesis, where primitive erythrocytes are generated in E7.5 embryos, are blood 
islands of the yolk sac. Blood islands of the yolk sac are in close associations with 
endothelial and haematopoietic cells, which led to the proposal of a common progenitor cell, 
for both cell types, the haemangioblast (Choi, 2002). At the beginning of E7, granulocyte-
macrophage progenitors and at E8.5, T- and B-lymphoid progenitors can be detected in the 
yolk sac (Cumano et al., 1993; Liu and Auerbach, 1991). The cells from intra-embryonic 
para-aortic splanchno-pleura seed the blood system of the embryo and the yolk sac at E8.5. 
Only short-term repopulating haematopoietic progenitors are generated in the yolk sac. At 
mid-E9 colony forming unit-spleen cells (CFU-S) are first detected in the AGM region and 
shortly after, at E10.5, HSCs that can repopulate the entire haematopoietic system are 
produced in the AGM region (Muller et al., 1994). The first CFU-S progenitors appear in the 
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dorsal aorta gonads-mesonephros (AGM) region at E9 (Medvinsky and Dzierzak, 1996) and 
the first long-term repopulating haematopoietic cells are detected at late E10 (Medvinsky and 
Dzierzak, 1996; Muller et al., 1994). Thus, the first definitive HSCs are produced in the AGM. 
 
The rudiment of the liver is formed at E9 from the evagination of the gut into septum 
transfersum. The liver does not generate its own haematopoietic cells but it is seeded from 
the yolk sac and AGM region at this stage of development. At E9, the liver contains 
erythroblasts and at E10, it starts to produce differentiated erythroid cells (Dzierzak and 
Medvinsky, 1995). At mid-E9, myeloid progenitors appear, at E10, T-cell progenitors and at 
E10-11, granulocyte-macrophage and B-lineage cells appear (Velardi and Cooper, 1984). At 
late E10-early E11 HSCs and CFU-S progenitors are detected in the developed foetal liver 
(Medvinsky and Dzierzak, 1996). 
 
Haematopoietic progenitors and stem cells in the adult mouse are found in bone marrow and 
spleen. The differentiated cells move quickly through the circulation to the other tissues and 
organs. Growth factors induce the efficient mobilization of haematopoietic precursors and 
stem cells into the blood (Bodine, 1995). Colonization of bone marrow with HSCs is believed 
to take place around E16 of gestation (Ogawa et al., 1988). According to Cumano et al. 
(1996), at E15, prior to bone formation, haematopoietic progenitors have already 
accumulated in bone marrow, but active B lymphopoiesis does not appear before 
E17(Cumano et al., 1996). With this background information we decided to use murine 
embryonic haematopoietic stromal cell lines derived from yolk sac such as yolk sac 
endodermal (YSE) and yolk sac mesodermal (YSM) (Yoder et al., 1995) AGM-derived DAS 
104-4 and DAS 104-8 (Ohneda et al., 1998) and AFT 024 (Moore et al., 1997) derived from 
foetal liver. Moreover, we took NIH 3T3 as a non-haematopoietic cell line. The specific 
characteristics of these cell lines play an important role in their capacity to contribute to the 
organs of developing embryos. These characteristics are described in detail below. 
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Figure 2. Development of the haematopoietic system in yolk sac, AGM and bone marrow leading 
to the generation of primitive and definitive haematopoiesis in mouse. In this study, many well 
described stroma cell lines derived from specific haematopoietic regions were used (See chapter 
3.6.1-3).  
 
3.6.1 Dorsal aorta stromal (DAS) 104-4 and DAS 104-8 cell lines 
 
These two cell lines are of endothelial origin. They were isolated from the murine AGM 
region as supportive cell lines for haematopoietic progenitors and HSCs (Ohneda et al., 
1998). To obtain endothelial cell lines, the AGM region of E11 murine embryo was isolated 
by dissection and cells were transformed using polyoma virus middle T- expressing 
retroviruses. This oncogene transforms endothelial cells and maintains them in an 
endothelial-like state (Bautch et al., 1987; Williams et al., 1989) Two morphologically similar 
CD34+ adherent cell lines DAS 104-4 and DAS 104-8 were selected. 
 
Analysis revealed that DAS 104-8 efficiently induced foetal liver HSCs to differentiate down 
erythroid, myeloid and B-lymphoid pathways, but did not mediate self-renewal of pluripotent 
cells. The DAS 104-4 cell line was inefficient at the induction of haematopoietic differentiation, 
but also provoked expansion of early haematopoietic progenitor cells and was proficient at 
maintaining foetal liver-derived HSCs (Ohneda et al., 1998). The morphology of these cell 
lines shows typical flattened, endothelial-like structure. They express a number of endothelial 
markers: CD34, FLT1, FLK1 (both are VEGF receptors), vWF and CD31 (platelet endothelial 
cell adhesion marker- PECAM). These cells produce the endothelial growth factor, VEGF, 
which may allow autocrine-mediated proliferation of these cell lines upon binding to the FLT1 
and FLK1. The formation of capillary-like structures, when these cells are grown in Matrigel 
also supports the fact that they are endothelial cells (Ohneda et al., 1998). Furthermore, DAS 
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104-4 was shown to be efficient in maintaining haematopoietic stem cells whereas DAS 104-
8 promotes differentiation of haematopoietic stem cells (Ohneda et al., 1998). 
 
3.6.2 Yolk sac endodermal (YSE) and Yolk sac mesodermal (YSM) cell 
lines 
 
These cell lines were established from the visceral endoderm and mesoderm of the yolk sac 
to better define the role of the murine yolk sac in differentiation and proliferation of the 
haematopoietic cells (Yoder et al., 1994). Yolk sacs from E9.5 murine embryos were isolated 
and separated endoderm and mesoderm layers were cultured. Adherent cells were infected 
with a recombinant retrovirus encoding SV40 large T antigen and permanent lines from yolk 
sac endoderm and mesoderm were established. The morphologies of the cell lines were 
similar to freshly isolated visceral cells. They showed polygonal morphology with formation of 
tight cell clusters. None of these cell lines were contact inhibited, and none showed 
anchorage-independent growth in soft agar. Polarized morphology, tight junctions, cell 
surface apical microvilli, coated pits and cytoplasmic coated vesicles were identified in these 
cells, which is characteristic of endocytically active yolk sac endoderm cells. Markers 
expressed on these cells are the extracellular matrix proteins - fibronectin, collagen IV, 
laminin, Endo-B cytokeratin, zonulla occludens-1 and GATA4. They do not express 
macrophage cell surface molecules Mac-1, F4/80, vimentin intermediate filaments, H513E3 
marker for stromal endothelial cells and one of the major secreted proteins in visceral yolk 
sac - α fetoprotein. Both YSE and YSM cell lines supported expansion of the BM cells 
depleted of committed progenitors by 5-FU treatment. However, YSE was proven to be more 
efficient in such maintenance activity than YSM (Yoder et al., 1995). This suggests that these 
cell lines recapitulate microenvironmental influences that exist in normal yolk sac (Yoder et 
al., 1994). Moreover, these cell lines significantly stimulate the proliferation of adult murine 
bone marrow high proliferative potential colony forming cells (HPP-CFC) in coculture (Yoder 
et al., 1995). 
 
3.6.3 The foetal liver AFT 024 cell line 
 
Cell line AFT 024 was derived from the foetal liver of a 14 to 14.5 day gestation mouse 
embryo (Moore et al., 1997). This cell line is immortalized with temperature sensitive SV40 T 
antigen. They represent cells obtained from the microenvironment of the liver that support 
purified mouse and human CD34+ CD38- haematopoietic stem/progenitor cells. Delta-like 
(Dlk1)/preadipocyte factor-1 (pref-1) is preferentially expressed in AFT 024 cells and 
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functions as a positive stem cell regulator (Moore et al., 1997). This cell line is widely used as 
stroma for ex vivo expansion of both human and murine haematopoietic precursor cells. 
 
 
 
3.7 Experimental strategy 
 
The microenvironment, in which a cell resides, may determine its fate. Here, I analyzed the 
consequences of stroma environment-induced changes in human AML cells upon in vitro 
coculture with murine embryo-derived haematopoietic stromal cells (Figure 3). 
 
In order to answer the question whether the stromal cells from mouse embryonic 
haematopoietic sites can reprogram human AML cells, the AML cells were cocultivated with 
stromal cells derived from murine foetal yolk sac, foetal liver or AGM region and any change 
in terms of immunophenotype was measured by immunostaining for myeloid specific 
markers. To determine whether the coculture-mediated differentiation of AML cells is 
accompanied by any coculture-induced change in cell cycle status and proliferation 
properties, the cell cycle status was analyzed and CFSE retention assay was done to 
analyze cell proliferation rate. Further, I addressed the question whether the coculture with 
stroma has any effect on colony forming cell pool of AML cells. By direct cocultivation of AML 
cells on feeder cells followed by re-seeding cocultured AML cells on semi-solid medium and 
scoring for the arising colonies, the effect of coculture on CFCs population was analyzed. To 
understand if the coculture-induced differentiation and change in proliferation need cell-cell 
contact between the feeder cells and AML cells, AML cells and feeder cells were indirectly 
cocultivated separated by membrane barrier and were analyzed for the coculture-induced 
changes. Furthermore, to look for molecular details and possible clue of the process 
responsible for the coculture-induced effect, I analyzed coculture-induced change in the 
expression profile of crucial myeloid transcription factors like RUNX1, PU.1 and C/EBPα by 
real time quantitative RT-PCR. Transcript levels of AML1-ETO oncogene and cell cycle 
regulator were also analyzed by real time RT-PCR. To understand the role of AML1-ETO 
transcript level down-regulation in coculture mediated effect on Kasumi-1 cells, AML1-ETO 
expression was knocked down using siRNA. Finally, to understand if the down-regulation of 
AML1-ETO have any role in coculture induced differentiation, I have further analyzed the 
effect of AML1-ETO knock down on colony formation efficiency, cell proliferation and AML 
cell differentiation together with the coculture. 
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Figure 3.  Experimental layout of the project, which includes direct and indirect cocultivation of 
human AML cell lines on murine stromal cells. Coculture-induced changes were measured in 
terms of morphology, immunochemistry, immunophenotype, proliferation properties, cell cycle 
status, fraction of colony forming cells in the population, and transcription status of some 
crucial genes. Furthermore, information-based manipulation of AML1-ETO gene expression by 
siRNA method was used to decipher the possible molecular players involved in stroma-
induced reprogramming of human AML cells. 
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4 RESULTS 
 
4.1 Myeloid marker expression following coculture of human AML 
cell line, Kasumi-1, on murine stromal cell lines 
 
Based on the previous studies in our laboratory, where AML cells were subjected to murine 
embryonic microenvironment by injecting into the day 3.5 murine blastocysts, and analysis of 
resulting embryos showed low level Chimaerism. However engrafted donor AML cells 
revealed no signs of leukaemia in mice derived from the recipient blastocyst. Furthermore, 
analyses of the donor AML cells in the embryo showed characteristics of erythroid 
differentiation (Durr et al., 2003). These findings lead to the hypothesis that the 
microenvironment of embryonic haematopoietic sites can affect and alter the nature of the 
AML cells and in turn it is possible that microenvironmental cues from the stromal cells 
derived from active embryonic haematopoietic sites can affect differentiation and proliferation 
properties of AML cells. Therefore, AML cell lines were cocultivated on characterized stromal 
cell lines originating from active embryonic haematopoietic sites such as yolk sac, foetal liver 
and the AGM region. Following coculture, the stroma coculture-induced changes in the AML 
cells were analyzed. Figure 4 shows effect of coculture on Kasumi-1 cells (Asou et al., 1991), 
a cell line derived from an AML1-ETO positive AML-M2 patient. Kasumi-1 cells were 
cocultured by seeding onto adherent and irradiated murine AGM region-derived DAS 104-4 
cells (Ohneda et al., 1998). After 6 days of direct coculture, cocultured Kasumi-1 cells were 
washed off the stromal cell layer, cytospun and examined for the appearance of 
differentiation markers by morphological and immunocytochemical analyses. Firstly, the 
morphology was analyzed by Pappenheim staining. Pappenheim staining gives the 
morphological details. The cytoplasmic granularity and the general morphology indicated 
myeloid maturation of the cocultured Kasumi-1 cells. In addition, staining for cytoplasmic 
CD68, which represents a lysosomal marker and was earlier reported to be up-regulated 
during monocytic differentiation, was used. Cells were stained with anti-CD68 antibody that 
reacts with a monocyte/macrophage-associated antigen (110Kd) to evaluate for myeloid 
differentiation (Greiner et al., 1997). As shown in Figure 4, cocultured Kasumi-1 cells 
acquired the morphology of monocytoid cells with increase in cytoplasmic vacuoles and 
granularity. Furthermore, upon cocultivation, Kasumi-1 cells showed cytoplasmic CD68 
immunoreactivity, approximately 30% of cells showed positive staining for cytoplasmic CD68. 
This result indicates that upon coculturing on AGM-derived DAS 104-4 cells, Kasumi-1 cells 
acquire differentiated morphology and cytoplasmic CD68. 
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Figure 4. Coculture-induced myeloid/monocytoid differentiation of Kasumi-1 cells. Representative 
sample stained by (A) Pappenheim or (B) Immunostaining for CD68 (Brown). Left panel shows 
non-cocultured Kasumi-1 cells whereas right panel shows Kasumi-1 cells cocultured on DAS 104-
4 for 6 days. Cells were harvested and cytospun on the objective slide. After air drying, the slides 
were analyzed by Prof. A. Greiner by Pappenheim and immunostaining for CD68. Magnifications: 
400X. 
 
 
4.2 DAS 104-4 coculture-induced acquisition of myeloid 
differentiation markers of Kasumi-1 cells 
 
Further, the coculture-induced effects on Immunophenotype of Kasumi-1 cells was analyzed. 
As shown in chapter 2.1, DAS 104-4 coculture-induced up-regulation of myeloid 
morphologies and immunochemistry in Kasumi-1 cells, I wanted to see if this result is 
consistent with up-regulation of myeloid immunophenotype i.e., CD11b and CD14 
(Heidenreich et al., 2003). Moreover, it would be interesting to see if stroma-induced 
differentiation promoting activity is stroma cell-specific. Therefore, I cocultivated Kasumi-1 
cells on DAS 104-4; murine foetal liver derived stromal cells, AFT 024 and mouse embryonic 
fibroblast derived cell line, NIH 3T3 as non-haematopoietic feeder. In parallel, the Kasumi-1 
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cells were treated with differentiation-inducing agent, all–trans retinoic acid (ATRA) as a 
positive control for myeloid differentiation (Manfredini et al., 1999). 
 
 
 
Figure 5. Coculture-induced changes in immunophenotype of Kasumi-1 cells. Representative 
flowcytometric analyses for CD11b, CD14 and propidium iodide stainings (A) of non-cocultured 
Kasumi-1 cells, (B) of Kasumi-1 cells following ATRA treatment and of Kasumi-1 cells cocultured 
for 3 days on (C) DAS 104-4, (D) NIH 3T3 or (E) AFT 024 cells. AML cells were stained with 
isotype control antibody, with human-specific CD11b or CD14 antibodies in combination with 
propidium iodide. Live gate on FSC/SSC profiles, enriched in living AML cells and depleted in 
stromal cells, was used to acquire the readings. Percentages of PI+ dead cells and of CD11b+ or 
CD14+ cells are indicated. Representative samples are shown (n>3). 
 
After 3 days of direct coculture, cocultured Kasumi-1 cells were washed off the stromal cell 
layer and harvested cells were examined for staining with either antibody isotype control to 
exclude any non-specific staining or anti-CD11b or anti-CD14 antibody to look for myeloid 
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differentiation. And to see if the staining signal is coming from the living cells, cells were 
double stained for propidium iodide (PI). As seen in Figure 5 and as described earlier 
(Manfredini et al., 1999), treatment with the differentiating agent all-trans retinoic acid (ATRA) 
induces CD11b up-regulation of Kasumi-1 cells indicative of myeloid differentiation. 
Furthermore, result shows that Kasumi-1 cells without coculture or cocultured on AFT 024 or 
NIH 3T3 cells for 3 days does not acquire either CD11b or CD14 staining. Only upon 
coculture with DAS 104-4 cells, Kasumi-1 cells acquire CD11b and CD14 staining. Propidium 
iodide staining of cocultured and non-cocultured cells indicate very low percentage of dead 
cells in the acquired gate. This result indicates that DAS 104-4 stroma can specifically induce 
Kasumi-1 cells to acquire myeloid differentiated immunophenotype. 
 
 
 
Table 4.  Appearance of myeloid immunophenotypes of cocultured human 
leukaemic cell lines 
  
No 
cocultivation YSE YSM DAS 104-4 DAS 104-8 AFT 024 NIH 3T3 ATRA 
Kasumi-
1 - - - + - - - + 
KG-1 + nd nd ++ nd nd ++ ++ 
EOL-1 - - nd - - nd nd nd 
NB-4 - nd nd + nd - - + 
M2-AML +/- nd nd + nd nd nd nd 
                 
 
Kasumi-1, KG-1, EOL-1, NB-4 cells and primary M2-AML cells were cocultured for 2-6 days on 
irradiated YSE, YSM, DAS 104-4, DAS 104-8, AFT 024 or NIH 3T3 cells. Following coculture, 
non-adherent cells were isolated by gentle washes and cells were analyzed for CD11b or CD14 
immunoreactivity by FACS. Samples that showed CD11b or CD14 staining are indicated as (+); 
samples that did not show CD11b or CD14 staining are labelled as (-); (+/-) stands for low (<10%) 
and (++) indicates high (>60%) CD11b or CD14 expression; nd: not done. As control for the 
induction of myeloid differentiation, cells were treated with all-trans retinoid acid (ATRA). Data 
shown represent the results of at least 2 individual experiments. 
 
 
 
 
 
4.3 DAS 104-4 stroma can induce myeloid differentiation of patient-
derived primary M2-AML cells 
 
In the present experiment, it was analyzed whether the DAS 104-4 stroma has the ability to 
induce differentiation of primary M2-AML cells. The M2-AML cells were derived from a 70 
year-old patient (kindly provided by Dr. R. Henschler, Frankfurt).  Cells were cocultivated on 
DAS 104-4 stromal cells for 2 days. Cocultured M2-AML cells were washed off the stromal 
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cell layer and harvested cells were examined for the appearance of differentiation markers by 
morphological and immunocytochemical analyses. Firstly, cells from cocultures were 
cytospun and the morphology was analyzed by Pappenheim staining. Cytoplasmic 
granularity and the nuclear structure indicated myeloid maturation of the cocultured patient-
derived primary M2-AML cells. Secondly, staining with anti-CD68 antibody was done to 
evaluate myeloid differentiation (Greiner et al., 1997). As shown in Figure 6, cocultured 
Kasumi-1 cells acquired the morphology of monocytoid cells with cytoplasmic CD68 
immunoreactivity, approximately 30-40% of primary M2-AML cells, cocultured on DAS 104-4 
cells, showed positive staining for cytoplasmic CD68, whereas <2% non-cocultured M2-AML 
cells showed positive staining for cytoplasmic CD68. This result indicates that upon 
coculturing on AGM-derived DAS 104-4 cells, primary M2-AML cells acquire monocytoid-
specific immunochemistry and morphology. 
 
 
Figure 6. Coculture-induced myeloid/monocytoid differentiation of patient-derived M2-AML cells. 
Shown are representative samples of (A) Pappenheim staining and of (B) CD68 immunostaining 
of non–cocultured patient-derived M2-AML cells (left) and of patient-derived M2-AML cells 
cocultured on irradiated DAS 104-4 cells (right). Non-cocultured or patient-derived M2-AML cells 
cocultured for 2 days were harvested and cytospun on objective slides. Air-dried slides were sent 
to Heidelberg to Prof. Axel Griener. Cells were there analyzed by Pappenheim staining or by 
CD68 (PGM1)-specific immunostaining (brown). Magnifications: 400X. 
 
In addition, the AML cells were harvested after 2 days of cocultivation and double stained 
with propidium iodide and  either isotype control antibody to rule out any non-specific staining 
or antibodies for myeloid markers CD11b, CD14 or the antibody against c-KIT. c-KIT is 
known as the receptor for stem cell factor hence, correlating to primitive progenitors/stem 
cells. Results indicate the fraction single positive for PI only consists of small fraction in all 
cases (Figure 7). It is interesting to see that the CD11b+ PI- cells increased from 4.3% in non-
cocultivated primary M2-AML cells to 28.1% upon cocultivation with DAS 104-4 cells. 
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Similarly, there was also cocultivation-induced increase in the CD14+ PI- primary M2-AML 
cells. Moreover, the result with c-KIT staining showed that there is a marginal decrease in c-
KIT+ PI- population upon cocultivation (Figure 7). In summary, Patient derived primary M2-
AML cells shows marked increase in myeloid differentiation markers, CD11b and CD14, in 
parallel with marginal decrease in primitive cell marker i.e., c-KIT in primary M2-AML cells 
when they are cocultivated on murine AGM-derived stromal cells, DAS 104-4. 
 
 
 
Figure 7.  M2-AML cells, derived from 70 year-old, male patient, were thawed and washed twice 
with culture medium to remove any traces of cryo-preservant. 8x105 cells were seeded onto 
irradiated DAS 104-4 stromal cells. After two days of coculture, cells were isolated, gently washed 
and AML cells were stained with isotype control antibody, human-specific antibodies against 
myeloid monocytic markers, CD11b or CD14 or the progenitor cell marker c-KIT in combination 
with PI. Live gate on FSC/SSC profiles, enriched in living AML cells and depleted in stromal cells, 
was used to acquire the readings. Percentages of PI+ dead cells and of CD11b+ or CD14+ or c-
KIT+ cells are indicated. Representative samples are shown (n=2). 
 
 
 
4.4 Effect of cocultivation on KG-1 AML cells 
 
KG-1 is an AML cell line. Previously, chimeric animals derived from blastocysts 
microinjection of KG-1, showed that upon introduction to the murine microenvironment, AML 
cells were undergoing change and started expressing elevated level of erythroid markers 
such as Glycophorin A and elevated level of β-globin expression. In the present study I 
asked the question, “What are the consequences of cocultivation of KG-1 cells on DAS 104-4 
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cells?” 
 
KG-1 cells were either grown alone or cocultured on DAS 104-4. After 3 days of direct 
coculture, KG-1 cells were washed off the stromal cell layer and harvested cells were 
examined for double staining with PI and either antibody isotype control to omit out any non-
specific staining or anti-CD11b antibody to look for myeloid differentiation. Figure 8 shows 
that the coculture of KG-1 cells on DAS 104-4 leads to increase in CD11b staining (non-
cocultured KG-1 cells: 25+15% CD11b+ cells; day 3 of coculture: 74+16% CD11b+ cells). In 
addition, propidium iodide staining of cocultured and non-cocultured cells indicate very low 
percentage of dead cells in the acquired gate. In summary, cocultivation on DAS 104-4, 
leads to increase in myeloid immunophenotype of KG-1 cells. 
 
 
 
 
Figure 8. Coculture-induced up-regulation of myeloid immunophenotype of KG-1 cells. 
Representative flowcytometric analyses of CD11b and PI stainings. (A) Non-cocultured KG-1 
cells stained with isotype control and PI (Left) and stained with CD11b (right). (B) KG-1 cells 
cocultured on DAS 104-4 for 3 days, stained with isotype (left) or CD11b human-specific antibody.  
AML cells were stained with isotype control antibody, with human-specific CD11b antibody in 
combination with PI. Live gate on FSC/SSC profiles, enriched in living AML cells and depleted in 
stromal cells, was used to acquire the readings. Percentages of PI+ dead cells and of CD11b+ 
cells are indicated. Representative samples are shown (n=3). 
 
 
As previously shown, KG-1 cells can be induced to undergo erythroid differentiation by 
introducing them into the murine embryonic microenvironment (Durr et al., 2003). Here, I 
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wanted to study the consequences of in vitro cocultivation on KG-1 cells in presence of DAS 
104-4 and its effect on erythroid markers. KG-1 cells were either grown alone (non-coculture) 
or cocultured on irradiated DAS 104-4 stromal layer. After coculture for 1, 2 and 3 days, KG-
1 cells were harvested, total RNA was extracted and cDNA was made. The transcription 
levels of β-globin were compared between the non-cocultured and cocultured KG-1 cells by 
human-specific  β-globin RT-PCR. 
 
Furthermore, It will be interesting to see whether there is any change in CD235a 
(Glycophorin A) expression on the KG-1 cell surface upon cocultivation. KG-1 cells either 
cultured alone or cocultured on irradiated DAS 104-4 stroma for 3 days. After cocultivation, 
KG-1 cells were harvested from the stromal layer and double stained with DAPI and anti-
CD235a antibody. 
 
RT-PCR result shows transcriptional up-regulation of β-globin gene upon cocultivation of KG-
1 on DAS 104-4, starting from 2nd day (Figure 9A). The immunostaining for human-specific 
Glycophorin A shows that higher level of staining is acquired when KG-1 is cocultivated on 
DAS 104-4 for 3 days (Figure 9B). This result indicates that KG-1 cells can acquire 
differentiated features when exposed to DAS 104-4 stroma environment in vitro, in a manner 
similar when they are exposed to embryonic environment in vivo. 
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Figure 9. Up-regulation of erythroid features in KG-1 upon DAS 104-4 coculture. (A) β-globin-
specific RT-PCR on RNA isolated from KG-1 cells either non-cocultured or cocultured on DAS 
104-4 for 1, 2 and 3 days. (B)  Immunostaining for Glycophorin A (CD235a), the left column 
shows non-cocultured KG-1 cells stained with DAPI and Glycophorin A antibody and the right 
column shows the KG-1 cells, cocultured on DAS 104-4 stromal cells for 3 days, stained with 
DAPI and Glycophorin A antibody. 
 
 
4.5 Coculture-induced change in proliferation properties of AML 
cells 
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Next, it was analyzed whether stroma-environment can change proliferation properties of 
human AML cells. I wanted to see, if there is any cocultivation-induced difference in cell cycle 
stage of Kasumi-1 cells. The results of cell cycle analysis of non-cocultured or cocultured 
Kasumi-1 cells by PI DNA staining revealed that coculture of Kasumi-1 on DAS 104-4 cells 
induces accumulation of cells in G1 phase and a  subsequent decrease of cells in S and G2/M 
phases (Figure 10). 
 
 
Figure 10. Analysis of cell cycle distribution. Cell cycle analysis by PI staining of non-cocultured 
(left) and of 2 days cocultured Kasumi-1 cells on DAS 104-4 (right). Percentages of cells in 
individual stages of the cell cycle are indicated. Showing one representative experiment of 3 
individual experiments. 
 
 
 
I further asked the question whether the coculture-induced accumulation of Kasumi-1 cells in 
G1 phase of cell cycle is also reflected as coculture-induced decrease in proliferation. To 
analyze the effect of coculture on AML cell proliferation rate, CFSE label retention assay was 
used (Lyons and Parish, 1994), where loss of CFSE serve as indication of cell proliferation 
rate. The distribution of cells according to their CFSE fluorescence was analyzed at 2, 4, 6, 
and 8 days of coculture (Figure 11). CFSE loss was decreased in Kasumi-1 cells cocultured 
on DAS 104-4 cells compared to the non-cocultured Kasumi-1 cells. There was no difference 
in CFSE dilution rates between the Kasumi-1 cells cocultivated on NIH 3T3 or without any 
stromal cells. This observation indicates that cocultivation with DAS 104-4 induces a specific 
reduction in cell proliferation rate of human AML cells.  
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Figure 11. Analysis of proliferation of Kasumi-1 cells. (A) Fluorescence profiles of CFSE-labelled 
Kasumi-1 cells that were either non-cocultured or cocultured on DAS 104-4 (left panels) or NIH 
3T3 (right panels) cells. Following CFSE labelling, Kasumi-1 cells were split into samples that 
were either cocultured or were kept without stroma cells. Shown are fluorescence profiles of 
labelled Kasumi-1 cells at the start of the experiment before coculture and after 2, 4, 6 and 8 days 
of coculture.  
 
4.6 DAS 104-4 induces decrease in total cell number and reduction 
in primitive colony forming cell pool of cocultured AML cell 
population 
 
As shown above, DAS 104-4 stroma induces accumulation of Kasumi-1 cells in G1 stage 
paralleled by decrease in CFSE dilution rate indicating a coculture-mediated reduction of cell 
proliferation. I further asked the question whether coculture has any effect on colony forming 
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cell (CFC) population in a given cell pool of Kasumi-1 cells. To achieve that, Kasumi-1 cells 
were cultured without stroma or cocultured on either DAS 104-4 or AFT 024 or NIH 3T3 for 4 
days. Counting of total number of trypan blue negative cells showed that there was 
significant decrease in total Kasumi-1 cell number when cocultivated on DAS 104-4 
compared to the cells without any cocultivation or cocultivated on AFT 024 or NIH 3T3 
stroma (Figure 12). Moreover, there was no significant difference between total number of 
viable cells when they were not cocultivated or cocultivated on NIH 3T3. Similarly, 
cocultivation of Kasumi-1 cells on AFT 024 did not show any change in total number of viable 
cells compared to the non-cocultivated. This result indicates that DAS 104-4 in particular 
exerts anti-proliferative effect on cocultivated Kasumi-1 cells and feeder derived from foetal 
liver AFT 024 and NIH 3T3 do not have such activity. 
 
Figure 12. Effect of coculture on the cell number of Kasumi-1 cells. 5x105 Kasumi-1 cells were 
seeded per well of a 6 well plate in the presence or absence of stromal cells (in triplicate). After 4 
days, Kasumi-1 cells were harvested from stromal cells and the total cell number per well was 
counted by trypan blue staining. 
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Figure 13. Effect of coculture on the clonogenicity of Kasumi-1 cells. 5x105 Kasumi-1 cells were 
seeded per well of a 6 well plate in the presence or absence of stromal cells (in triplicate). After 4 
days, Kasumi-1 cells were harvested from stromal cells and (A) non-cocultured and cocultured 
cells were seeded into semi-solid methyl cellulose medium and 14 days after plating colony 
numbers were counted. (B) Total number of CFCs after 4 days with or without coculture. The total 
CFC numbers were calculated by multiplication of viable cell numbers/well (taken from Figure 14) 
with CFCs/5000 cell numbers (from Figure 15A). Cells/well, CFCs/5000 cells and total numbers 
of CFCs/well are indicated; error bars show standard deviations (n=3). Statistical significance was 
tested by Student t-test. (*) indicates P<0.05; (**) stands for P<0.01. 
 
 
 
 
 
In addition, it was analyzed whether cocultivation with DAS 104-4 has any effect on colony 
forming cell fraction of Kasumi-1 cell population. These CFCs are supposed to be primitive 
cells, which drive total population. Kasumi-1 cells were either cultured without any feeder 
cells or cocultivated on either DAS 104-4 or AFT 024 or NIH 3T3 cells for 4 days. Viable cells 
were counted by their tryphan blue exclusion capability. 5000 viable cells from cultures were 
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seeded on semi-solid methyl cellulose plates. Colonies were let to grow in 37°C humidified 
incubator for 14 days. Results showed no significant difference between colony numbers of 
non-cocultivated Kasumi-1 cells and that of Kasumi-1 cells cocultivated on NIH 3T3 or AFT 
024. In contrast, significant decrease in the colony numbers were observed, when they are 
cocultured on DAS 104-4 in comparison to the Kasumi-1 cells without cocultivation or 
cocultivated on NIH 3T3 or AFT 024 (Figure 13). Furthermore, I calculated the absolute 
number of colony forming cells of Kasumi-1 cells, which were either cultured alone or 
cocultured on DAS 104-4, AFT 024 or NIH 3T3. Results showed that absolute number of 
colony forming cells decreased to less than 1% of non-cocultured Kasumi-1 cells when they 
were cocultured on DAS 104-4. Whereas, there was no significant difference between the 
non-cocultivated Kasumi-1 cells and the Kasumi-1 cells cocultivated on AFT 024 or NIH 3T3. 
These results indicate that DAS 104-4 microenvironment can specifically and significantly 
reduce the total colony forming cell fraction of Kasumi-1 cell pool. 
 
 
 
 
4.7 Effects of direct and indirect coculture 
 
I asked the question whether the coculture-induced effect of DAS 104-4 needs direct cell to 
cell contact between stromal cells and AML cells or it is mediated through some soluble 
factor(s). In that case I can see the effect even if the stroma and AML cells are placed apart 
by a permeable transmembrane. In the present experiment, AML cells were either cultured 
alone or cocultivated directly on feeder cells or indirectly cocultured, separated from feeder 
layer by 0.4µm pore-size permeable transmembrane. 
 
 
Kasumi-1 cells were stained with CFSE and then split them to seed either alone or directly 
on irradiated feeder layer of DAS 104-4 or across the transwell for indirect cocultivation and 
then looked over window of time for CFSE dilution which in turn related directly to the cell 
proliferation rate of Kasumi-1 cells. The result (Figure 14) indicated that direct cocultivation 
has maximum effect on proliferation reduction capability, whereas, Kasumi-1 cells cocultured 
indirectly on transwell shows lesser degree of proliferation reduction. This study indicates 
that to exert maximum efficacy on Kasumi-1 cells in terms of cell proliferation inhibition, DAS 
104-4 stroma needs direct cell to cell contact with AML cells.  
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Figure 14.  Effect of direct versus indirect coculture on proliferation of AML cells. CFSE-labelled 
Kasumi-1 cells were either non-cocultured or directly cocultured on DAS 104-4 cells or labelled 
Kasumi-1 cells and DAS 104-4 cells were seeded in opposite sides of a 0.4µm pore-size 
polycarbonate membrane (transwell). CFSE fluorescence of Kasumi-1 cells was recorded at 2, 4 
or 6 days post start of coculture. A representative experiment is shown (n=3). 
 
 
 
 
 
Furthermore, I asked the question whether the Kasumi-1 differentiation promotion activity of 
DAS 104-4 feeder cells indeed need direct cell to cell contact or it can be facilitated through 
soluble factor when stroma and AML cells are separated by permeable membrane. To 
address this, Kasumi-1 cells were cocultivated for 3 days either directly on irradiated feeder 
cells or indirectly when the AML and feeder cells were separated by 0.4µm pore-size 
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permeable transmembrane and I compared these with the Kasumi-1 cells cultured without 
any stromal cells for 3 days. AML cells were harvested after 3 days post culture and either 
stained with isotype control antibody to rule out any non-specific staining or stained with anti-
CD11b antibody to indicate myeloid differentiation. Results (Figure 15) indicate that only 
Kasumi-1 cells cocultured directly on DAS 104-4 showed induction of myeloid differentiation, 
whereas, the Kasumi-1 cells indirectly cocultured on DAS 104-4 showed no staining for 
myeloid differentiation as similar to the Kasumi-1 cells cultured without any feeder. From this 
result it is evident that the direct stroma-AML cell contact is required for coculture-induced 
myeloid differentiation of Kasumi-1 cells by DAS 104-4 stroma. 
 
 
 
Figure 15. Effect of direct versus indirect coculture on AML differentiation. Upper row shows 
Kasumi-1 cells cultured for 3 days without stroma. Middle row represents Kasumi-1 cells 
cocultured on DAS 104-4 for 3 days either directly or indirectly. Lower row shows Kasumi-1 cells 
cocultured directly or indirectly on NIH 3T3 for 3 days. AML cells were stained with isotype control 
antibody or with human-specific CD11b antibody in combination with PI. Live gate on FSC/SSC 
profiles, enriched in living AML cells and depleted in stromal cells, was used to acquire the 
readings. Percentages of PI+ dead cells and of CD11b+ cells are indicated. Representative 
samples are shown (n=3). 
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4.8 Effect of fixed DAS 104-4 in reduction of proliferation and 
induction of differentiation of cocultured Kasumi-1 cells 
 
I asked question, whether the fixed DAS 104-4 is sufficient to induce proliferation reduction of 
AML cells. To answer our question, Kasumi-1 cells were labelled with CFSE and cultured 
them as either non-cocultured or directly cocultivated Kasumi-1 cells either on the living or on 
fixed stromal layer of DAS 104-4. Kasumi-1 cells were harvested after 3 days of coculture 
and CFSE fluorescence retention was measured using flowcytometry. The fluorescence 
measurement in Figure 16 indicates that fluorescence reduction was maximum in non-
cocultured Kasumi-1 cells, this indicates that the Kasumi-1 cell proliferation rate was 
maximum when they were not cocultured with DAS 104-4. Kasumi-1 cells cocultivated on 
paraformaldehyde-fixed stroma cells showed lower CFSE loss compared to the non-
cocultured Kasumi-1 cells, that indicates that the proliferation rate of Kasumi-1 cells on fixed 
DAS 104-4 is lesser than that of Kasumi-1 cells grown without stroma. The Kasumi-1 cells 
cocultured on living (unfixed) DAS 104-4 cells showed maximum CFSE retention, i.e., 
maximum AML cell proliferation inhibition activity. In summary, living DAS 104-4 stroma can 
most effectively induce cell proliferation inhibition, than the PFA-fixed DAS 104-4 stroma 
which in turn shows marginally reduced cell proliferation inhibition than the Kasumi-1 cells 
grown without any DAS 104-4 stroma. This indicates that living DAS 104-4 stroma is required 
to induce maximum reduction in proliferation of Kasumi-1 cells. 
 
Figure 16.  Effect of physiologically active versus fixed DAS 104-4 stroma layer on proliferation of 
cocultured Kasumi-1 cells. (A) Unlabelled and CFSE-labelled Kasumi-1 cells at the start. (B) 
CFSE-labelled Kasumi-1 cells were directly cocultured on either living or fixed DAS 104-4, or 
indirectly cocultured by seeding Kasumi-1 cells and DAS 104-4 cells in opposite sides of a 0.4µm 
pore-size polycarbonate membrane (transwell). CFSE fluorescence of Kasumi-1 cells was 
recorded at 3 days post start of coculture. A representative experiment is shown (n=2). 
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4.8.1 Effect of fixed stroma on differentiation 
 
The question addressed here is whether the fixed DAS 104-4 is sufficient to induce myeloid 
differentiation in AML cells. To address this question, Kasumi-1 cells were cultured alone or 
directly cocultured either on the living or on the fixed stromal layer of DAS 104-4. In addition 
to that, Kasumi-1 cells, indirectly cocultured on living DAS 104-4, were also included in this 
study. Kasumi-1 cells were harvested after 3 days of coculture and stained with isotype 
control or myeloid marker CD11b-specific antibody. Figure 17 shows that Kasumi-1 cells 
cocultured on fixed stromal cells showed no CD11b staining, i.e., showed no sign of myeloid 
differentiation, similar to the Kasumi-1 cells cultured without stromal cells, whereas, Kasumi-
1 cells directly cocultivated on living (unfixed) DAS 104-4 showed positive staining for CD11b. 
These results indicate that metabolically active DAS 104-4 is required for its myeloid 
differentiation inducing activity in AML cells. 
 
Figure 17. Comparison of direct cocultivation on physiologically active DAS 104-4 stroma versus 
fixed stroma on AML differentiation inducing capability. Flowcytometric analysis of CD11b, CD14 
and PI stainings of (A) non-cocultured Kasumi-1 cells, (B) Kasumi-1 cells cocultured for 3 days 
directly on living DAS 104-4 cells, (C) Kasumi-1 cells cocultured directly on 2% PFA-fixed DAS 
104-4 stromal cells and (D) Kasumi-1 cells cocultured indirectly on DAS 104-4 stromal cells 
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where AML and stroma were separated by transmembrane with 0.4µm pore size. Following 
coculture, AML cells were stained with isotype control antibody, with human-specific CD11b or 
CD14 antibodies in combination with PI. Live gate on FSC/SSC profiles, enriched in living AML 
cells and depleted in stromal cells, was used to acquire the readings. Percentages of PI+ dead 
cells and of CD11b+ or CD14+ cells are indicated. Representative samples are shown (n=2). 
 
 
4.9 Effect of DAS 104-4 stroma on Kasumi-1 AML1-ETO expression 
 
As AML1-ETO fusion gene is present in 40% of M2-AML and this fusion oncogene is present 
in Kasumi-1 cells, it was studied whether there is any specific change in AML1-ETO 
transcription following coculture of Kasumi-1 cells on DAS 104-4. 
 
4.9.1 DAS 104-4 induced reduction in AML1-ETO transcript level of 
cocultivated Kasumi-1 cells 
 
To look for DAS 104-4 coculture induced molecular consequences in Kasumi-1 cell, I 
compared the transcript level of AML1-ETO in Kasumi-1 cells cultured alone or cocultured 
either on DAS 104-4 or NIH 3T3 or AFT 024 for 3 days. Figure 18 shows more than 10-fold 
decrease in AML1-ETO transcript level of Kasumi-1 cells cocultured on DAS 104-4 cells 
compared to that of Kasumi-1 cells which are non-cocultivated or cocultivated on either NIH 
3T3 or AFT 024.  
 
Figure 18. Quantitative AML1-ETO RT-PCR analysis. Total RNA was isolated from non-
cocultured Kasumi-1 cells or from direct cocultures of Kasumi-1 cells on DAS 104-4, NIH 3T3 or 
AFT 024 cells at day 3 of coculture. The relative mRNA levels of AML1-ETO were normalized by 
β-actin-specific RT-PCR. Gene expression of tested mRNAs in non-cocultured Kasumi-1 cells 
was set to 1 (n=3). PCR primers are human-specific.  
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4.9.2 Stroma-AML contact-dependent down-regulation of AML1-ETO 
transcription 
 
As it was shown in the previous section that there is coculture-induced down-regulation of 
AML1-ETO transcript level, I further went ahead to ask the question whether the DAS 104-4 
stroma-induced AML1-ETO transcriptional down-regulation is contact-dependent. Figure 19 
shows that direct cocultivation of Kasumi-1 cells on DAS 104-4 stroma for 3 days leads to 
significant reduction in AML1-ETO transcription compared to that of non-cocultured Kasumi-1 
cells. In contrast, Kasumi-1 cells indirectly cocultured on DAS 104-4 showed no significant 
change in the AML1-ETO transcript levels compared to non-cocultured Kasumi-1 cells.  
 
 
Figure 19. Effect of direct and indirect coculture on AML1-ETO transcript level in Kasumi-1 cells. 
Total RNA was isolated from non-cocultured Kasumi-1 cells or from Kasumi-1 cells directly or 
indirectly cocultured on DAS 104-4 for 3 days. The relative mRNA levels of AML1-ETO were 
normalized by β-actin-specific RT-PCR. Gene expression of tested mRNAs in non-cocultured 
Kasumi-1 cells was set to 1 (n=3). PCR primers are human-specific. 
 
 
 
 
4.10 CD44 ligation-induced differentiation of AML cells 
 
It has been shown (Charrad et al., 1999) that many AML primary and established cell lines 
can be induced to differentiate by activation of CD44 receptor by ligation with CD44–ligating 
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antibody. Here, the possibility of CD44 activation being the mechanism of observed DAS 
104-4 cocultivation-induced myeloid differentiation of Kasumi-1 cells was checked. 
 
4.10.1 Expression of CD44 on Kasumi-1, KG-1 and NB-4 cells 
 
I looked for CD44 expression on AML cell lines, Kasumi-1, KG-1 and NB-4. Staining with the 
CD44–ligating antibody (A3D8) and FACS analyses showed that all three cell lines express 
CD44 on their surface with similar intensities (Figure 20). 
 
 
Figure 20. Expression of CD44 on the surface of different AML cell lines. (A) Kasumi-1 (B) KG-1 
and (C) NB-4. Cells were stained with mouse anti-human CD44 antibody, clone A3D8, 
subsequently stained with rabbit anti-mouse secondary antibody coupled with Cy3 chromophore 
(n=3). 
4.10.2 CD44-ligating antibody, A3D8 mediated differentiation of AML cells 
 
As CD44 ligation can induce myeloid differentiation of human AML cells (Charrad et al., 
1999), I addressed the question whether CD44 activation is the mean by which cocultivation 
is mediating its myeloid differentiating effect on AML cells. AML cells, Kasumi-1, KG-1 and 
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NB-4 were incubated, either with 20µg/ml concentration of CD44 activating antibody, A3D8 
or same concentration of IgG1 isotype control. Cells were harvested after 3 days of 
incubation and were either stained with isotype control to rule out any non-specific staining or 
stained with antibody against myeloid marker, CD11b. Second staining with PI was done to 
be sure that the signal is not coming from the dead cells. I observed myeloid differentiation in 
NB-4 (no CD44 activation: 0.07+0.03% CD11b+ cells; day 3 of CD44 treatment: 27.6+10.3% 
CD11b+ cells) and KG-1 cells (no CD44 activation: 59.2+6.1% CD11b+ cells, day 3 of CD44 
treatment: 92.6+5.7% CD11b+ cells). In contrast, CD44 treatment of Kasumi-1 cells did not 
induce myeloid differentiation (no CD44 activation: 0.03+0.04% CD11b+ cells, day 3 of CD44 
treatment: 0.05+0.03% CD11b+ cells). This result indicates that CD44 activation by itself is 
not sufficient to induce myeloid differentiation in Kasumi-1 cells (Figure 21). 
 
 
Figure 21. Effect of CD44-ligating (activating) antibody on differentiation of AML cells. Kasumi 1 
cells were either incubated with isotype control antibody (20µg/ml) or same concentration of 
CD44-ligating antibody for 3 days. Upper row shows Kasumi-1 incubated either in isotype control 
antibody (left two) or incubated with A3D8 (right two). Middle row shows KG-1 incubated either in 
isotype control antibody (left two) or incubated with A3D8 (right two). Lower row shows NB-4 
incubated either in isotype control antibody (left two) or incubated with A3D8 (right two). 
Flowcytometric analyses of CD11b and PI stainings. AML cells were stained with isotype control 
antibody or with human-specific CD11b antibody in combination with PI. Live gate on FSC/SSC 
profiles, enriched in living AML cells and depleted in stromal cells, was used to acquire the 
readings. Percentages of PI+ dead cells and CD11b+ cells are indicated. Representative samples 
are shown (n=3). 
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4.11 Gene expression analysis of critical mediators of proliferation 
and myeloid differentiation 
 
Since coculture-mediated reduction in proliferation and induction of myeloid differentiation 
were observed as described in the previous sections, I wanted to see if these manifestations 
are accompanied by alteration in expression of differentiation-associated and cell cycle 
regulator genes. 
4.11.1 PU.1 
 
PU.1 transcription factor plays an important role in myeloid differentiation and it was 
previously shown that mice PU.1 hypomorphs shows myeloproliferative disorders (Mueller et 
al., 2002), suggesting its important role in myeloid differentiation pathway. Therefore, the 
transcript level of PU.1 between Kasumi-1 cells cocultured on DAS 104-4 and Kasumi-1 cells 
cultured without any feeder cells was compared. The result indicates increase in the PU.1 
transcript level of cocultured Kasumi-1 cells (Figure 22). 
 
 
Figure 22. Quantitative RT-PCR analysis for PU.1 transcript level. Total RNA was isolated from 
non-cocultured Kasumi-1 cells or from direct coculture of Kasumi-1 on DAS 104-4 cells at day 3 
of coculture. The relative mRNA levels of PU.1 were normalized by β-actin-specific RT-PCR. 
Gene expression of tested mRNAs in non-cocultured Kasumi-1 cells was set to 1 (n=3). PCR 
primers are human-specific.  
 
 
Results 
 
46 
4.11.2 RUNX1 (AML1) 
AML1; also known as runt-related transcription factor 1, or RUNX1. This gene  was originally 
cloned from the breakpoint of the t(8;21) reciprocal chromosome translocation and was later 
recognized as one of the most frequent targets of leukaemia-associated gene aberrations. 
Gene-targeting experiments revealed that transcriptionally active AML1 is essential for the 
establishment of definitive haematopoiesis (Okuda et al., 2001). Moreover, as shown in 
previous section that the direct DAS 104-4 coculture induces significant decrease in AML1-
ETO transcript level in Kasumi-1 cells, Therefore, I asked the question whether there is any 
difference in transcript level of RUNX1. As the 5’ upstream gene region of AML1 is retained 
in AML1-ETO gene, the transcript level of AML1 between Kasumi-1 cells cocultured on DAS 
104-4 and Kasumi-1 cells cultured without any feeder cells was compared. This result 
indicates substantial decrease in the AML1 transcript level of cocultured Kasumi-1 cells 
compared to that of non-cocultured Kasumi-1 cells (Figure 23). 
 
 
Figure 23. Quantitative RT-PCR analysis for RUNX1 transcript level. Total RNA was isolated 
from non-cocultured Kasumi-1 cells or from direct coculture of Kasumi-1 on DAS 104-4 cells at 
day 3 of coculture. The relative mRNA levels of RUNX1 were normalized by β-actin-specific RT-
PCR. Gene expression of tested mRNAs in non-cocultured Kasumi-1 cells was set to 1 (n=3). 
PCR primers are human-specific.  
 
 
 
 
 
 
4.11.3 C/EBPα  
 
C/EBPα is one of the myeloid transcription factors, the role of which is lot more implicated in 
myeloid differentiation (Zhang et al., 1996). It has been shown that the C/EBPα protein 
directly interacts with CDK2 and CDK4 and arrests cell proliferation by inhibiting these 
Results 
 
47 
kinases. A region between amino acids 175 and 187 of C/EBPα was determined to be 
responsible for direct inhibition of cyclin-dependent kinases and caused growth arrest in 
cultured cells (Wang et al., 2001). Apart from this C/EBPα  can also exert its proliferation 
inhibitory effect through the p21(WAF) (Timchenko et al., 1996). Therefore, I compared the 
transcript level of C/EBPα between Kasumi-1 cells cultured without any feeder or cocultured 
on either DAS 104-4 or AFT 024 or NIH 3T3. The result indicates increase in the C/EBPα 
transcript level when the Kasumi-1 is cocultured on DAS 104-4 (Figure 24). 
 
 
Figure 24. Quantitative RT-PCR analysis of C/EBPα. Total RNA was isolated from non-
cocultured Kasumi-1 cells or from direct cocultures of Kasumi-1 cells on DAS 104-4, NIH 3T3 or 
AFT 024 cells at day 3 of coculture. The relative mRNA levels of C/EBPα were normalized by β-
actin-specific RT-PCR. Gene expression of tested mRNAs in non-cocultured Kasumi-1 cells was 
set to 1 (n=3). PCR primers are human-specific.  
 
 
 
 
 
 
4.11.4 p16 (INK4A) 
 
p16 is important cell cycle regulatory factor which inhibits CDK4 and causes G1 checkpoint 
arrest. As DAS 104-4 coculture induce reduction of AML cell proliferation accompanied by 
accumulation of cells in G1 phase, I compared the transcript level of p16 between Kasumi-1 
cells cocultured on either DAS 104-4 or NIH 3T3 or AFT 024 and Kasumi-1 cells cultured 
without any feeder cells. The result indicates increase in the p16 transcript level of Kasumi-1 
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cells cocultured on DAS 104-4 stromal cells compared to that of non-cocultivated Kasumi-1 
cells. Kasumi-1 cells cocultivated on NIH 3T3 also showed elevated level of p16 transcript, 
leading us to conclude that p16 transcript level up-regulation is not DAS 104-4 coculture-
specific (Figure 25).    
 
Figure 25. Quantitative RT-PCR analysis of p16. Total RNA was isolated from non-cocultured 
Kasumi-1 cells or from direct cocultures of Kasumi-1 cells on DAS 104-4, NIH 3T3 or AFT 024 
cells at day 3 of coculture. The relative mRNA levels of p16 were normalized by β-actin-specific 
RT-PCR. Gene expression of tested mRNAs in non-cocultured Kasumi-1 cells was set to 1 (n=3). 
PCR primers are human-specific.  
 
 
 
 
 
 
 
4.11.5 p21(WAF) 
 
p21 is an important cell cycle regulatory factor, which inhibits cyclin dependent kinase-1,-2,-4 
& 6 and causes checkpoint arrest. Apart from being a cell cycle control protein, its role in 
differentiation is also been previously indicated (Harper et al., 1993). I compared the 
transcript level of p21 between Kasumi-1 cells cocultured on either DAS 104-4 or NIH 3T3 or 
AFT 024 and Kasumi-1 cells cultured without any feeder cells. The result indicates 
considerable increase in the p21 transcript level of Kasumi-1 cells cocultured on DAS 104-4 
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stromal cells compared to non-cocultured Kasumi-1 cells as well as Kasumi-1 cells 
cocultured on NIH 3T3 or AFT 024 (Figure 26). 
 
 
 
Figure 26. Quantitative RT-PCR analysis of p21. Total RNA was isolated from non-cocultured 
Kasumi-1 cells or from direct cocultures of Kasumi-1 cells on DAS 104-4, NIH 3T3 or AFT 024 
cells at day 3 of coculture. The relative mRNA levels of p21 were normalized by β-actin-specific 
RT-PCR. Gene expression of tested mRNAs in non-cocultured Kasumi-1 cells was set to 1 (n=3). 
PCR primers are human-specific.  
 
 
 
 
 
 
In summary, quantitative RT-PCR of RNAs from cocultured Kasumi-1 cells with human-
specific primers showed that the coculture-induced down-regulation of AML1-ETO is 
paralleled by an increase in C/EBPα, p16 (INK4A) and p21 (WAF) expression. Therefore, 
coculture of Kasumi-1 on DAS 104-4 cells results in the decrease of AML1-ETO transcription 
and in the increase in transcription of regulators associated with differentiation and cell cycle 
regulation. 
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4.12 AML1-ETO siRNA decreases proliferation and induces myeloid 
differentiation of cocultured Kasumi-1 cells 
 
As DAS 104-4 coculture induces down-regulation in the transcript level of AML1-ETO. I 
further analyzed if the down-regulation itself can promote differentiation, or if AML1-ETO 
transcription down-regulation act in concert with coculture derived signal. This question was 
addressed by employing siRNA to specifically down-regulate AML1-ETO expression.  
 
 
 
4.12.1 siRNA transfection efficiency  
 
siAM (siRNA against AML1-ETO) sequence were adapted from Heidenreich et al. 
(Heidenreich et al., 2003). To optimize out the best siRNA transfection conditions for Kasumi-
1 cells. I titrated between different concentrations of fluorescent-labelled siAM and amount of 
transfectinTM reagent per transfection. 8X105  Kasumi-1 cells were transfected using shown 
concentrations of FAM labelled siAM and transfectinTM agent. After 24hr post transfection, 
cells were harvested, washed and analyzed by flowcytometry for the incorporated 
fluorescent-labelled siRNA. The result shows that the siAM transfection efficacy can be 
brought to as high as 83% by using 1µg of siRNA and 4µl of transfectinTM reagent per 
transfection reaction (Figure 27).  
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Figure 27. Transfection of FAM labelled siAM. Kasumi-1 cells were transfected with different 
concentrations of siRNA specific to AML1-ETO (siAM) labelled with fluorescent dye, FAM 
(different columns). Different amounts of transfection agent, transfectinTM, were also tested 
(different rows). Cells were washed 24hr post transfection and flowcytometric analyses were 
done to analyze intracellular siAM positive cells. Percentages of siAM+ cells are indicated. 
 
 
4.12.2 siRNA mediated down-regulation of AML1-ETO expression 
 
Total RNA was isolated 48 hour post-transfection from Kasumi-1 cells either mock 
transfected (without any siRNA) or transfected either with AML1-ETO specific siRNA (siAM) 
or control siRNA (siCTL). The quantitative RT-PCR result shows no significant difference in 
AML1-ETO transcript level between Kasumi-1 cells either transfected with control siRNA or 
no siRNA. In contrast, Kasumi-1 cells transfected with siAM show significant decrease in 
AML1–ETO transcript level (Figure 28). 
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Figure 28. Quantitative RT-PCR analysis of AML1-ETO. Total RNA was isolated 48hr post-
transfection of Kasumi-1 cells either without any siRNA or with non-specific siRNA or with siAM. 
The relative mRNA levels of AML1-ETOwere normalized by β-actin-specific RT-PCR. Gene 
expression of tested mRNAs of untransfected Kasumi-1 cells was set to 1 (n=3). PCR primers are 
human-specific. 
 
 
 
4.12.3 siRNA mediated reduce in colony formation efficiency 
 
Here I addressed the question whether the AML1-ETO knock-down alone has any effect on 
colony forming cell fraction of Kasumi-1 cell population. 24 hour post-transfection with siAM 
or siCTL, 5000 Kasumi-1 cells were seeded per methyl cellulose plate and the plates were 
incubated in humidified 37°C incubator for 14 days. Result shows that Kasumi-1 cells 
transfected with siAM showed reduced number of colony forming cells in the population pool 
compared to the cells transfected with siCTL. This result (Figure 29) indicates that knocking 
down of AML1-ETO gene transcription alone can lead to significant decrease in colony 
forming cells in the AML cell pool. This result is comparable to the previously reported data 
(Heidenreich et al., 2003). 
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Figure 29. Effects of AML1-ETO knock-down on the clonogenicity of Kasumi-1 cells. 8X105 
Kasumi-1 cells were transfected with either control siRNA or siRNA specific to AML1-ETO (siAM). 
Cells were harvested 48hr post-transfection and seeded on methyl cellulose plates (5000 
cells/plate) and 14 days after plating, colony numbers were scored (n=3). 
 
 
 
 
4.12.4 siRNA mediated reduction in cell proliferation 
 
Previously, I have seen coculture-induced down-regulation of AML1-ETO expression in 
Kasumi-1 cells in parallel with reduction in proliferation. Here I asked the question if AML1-
ETO gene expression knock-down alone is sufficient to induce cell proliferation reduction in 
AML cells. I labelled the cells with CFSE and then split them to transfect with either siAM or 
siCTL. Subsequently, transfected cells were analyzed on 2, 3 and 4 day for CFSE retention 
by flowcytometry. The result shows that the Kasumi-1 cells transfected with siAM showed 
lower rate of CFSE loss compared to the Kasumi-1 cells transfected with siCTL (Figure 30). 
Therefore, knocking down AML1-ETO expression alone in Kasumi-1 cell leads to lower 
proliferation rates compared to the Kasumi-1 cells transfected with control siRNA.  
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Figure 30. Effect of siRNA mediated knock-down of AML1-ETO transcription on proliferation rate 
of Kasumi-1 cells. Following CFSE labelling, Kasumi-1 cells were split and transfected with either 
control siRNA or siAM. Fluorescence profiles of the transfected CFSE-labelled Kasumi-1 cells are 
shown at the start and after 2, 3 and 4 days of coculture (n=2). 
 
 
 
 
 
 
 
Results 
 
55 
4.12.5 Effect of AML1-ETO knock-down on DAS 104-4 induced 
differentiation of Kasumi-1 cells 
 
As DAS 104-4 coculture induces down-regulation in AML1-ETO transcript level in parallel 
with coculture-induced up-regulation in myeloid markers in Kasumi-1 cells, I asked the 
question if coculture-induced AML1-ETO down-regulation plays any role in DAS 104-4 
stroma-induced myeloid differentiation in Kasumi-1 cells or they are just parallel events. 
Kasumi-1 cells were transfected with either siCTL or siAM. Transfected Kasumi-1 cells were 
either cultured without stromal cells or cocultured on either NIH 3T3 or DAS 104-4 cells for 3 
days. Result shows that non-cocultured Kasumi-1 cells or Kasumi-1 cells cocultured on NIH 
3T3, irrespective of either transfected with either siCTL or siAM, did not show any CD11b or 
CD14 staining. Therefore, it implicates that AML1-ETO transcription down-regulation by itself 
is not sufficient to induce myeloid differentiation of Kasumi-1 cells. Furthermore, only upon 
direct coculture on DAS 104-4, siAM transfected Kasumi-1 cells showed higher levels of 
CD11b and CD14 specific staining compared to the cocultured Kasumi-1 cells transfected 
with siCTL. These results indicate that AML1-ETO down-regulation alone in Kasumi-1 cells is 
insufficient to induce myeloid differentiation and it can only work synergistically along with 
coculture on DAS 104-4 stromal cells (Figure 31). 
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Figure 31. Effects of AML1-ETO siRNA-mediated down-regulation on cocultured Kasumi-1 cells. 
(A) non-cocultured Kasumi-1 cells transfected with siCTL. (B) non-cocultured Kasumi-1 cells 
transfected with siAM. (C) Kasumi-1 cells transfected with siCTL, cocultured on DAS 104-4 cells. 
(D) Kasumi-1 cells transfected with siAM, cocultured on DAS 104-4 cells. (E) Kasumi-1 cells 
transfected with siCTL, cocultured on NIH 3T3 cells. (F) Kasumi-1 cells transfected with siAM, 
cocultured on NIH 3T3 cells. Percentages of PI+ dead cells, of CD11b+ and CD14+ cells are 
indicated. FACS analyses were done after 3 days of coculture with transfected cells. Live gate on 
FSC/SSC profiles, enriched in living AML cells and depleted in stromal cells, was used to acquire 
the readings. A representative experiment is shown (n=3). 
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5 DISCUSSION 
 
Aim of this study was to analyze the effect of stroma environment on leukaemic cells in vitro. 
It is known that normal haematopoietic cell proliferation and differentiation in vivo are tightly 
regulated both by soluble factors as well as complex network of cell-to-cell contacts provided 
by the stromal cells in their niche. Moreover, the picture generating from molecular and 
functional data indicates that molecular crosstalk between normal haematopoietic cells and 
their niche is orchestrated by large number of molecules like cadherins, integrins, 
chemokines, cytokine signalling molecules and receptors. It is well documented that stromal 
cell lines isolated from embryonic or foetal haematopoietic sites maintain or even support 
HSC activity ex vivo (Moore et al., 1997; Ohneda et al., 1998; Oostendorp et al., 2002; Yoder 
et al., 1995). While some stroma cells support HSC maintenance other stromal cell lines 
induce haematopoietic differentiation (Ohneda et al., 1998; Yoder et al., 1994). Therefore, 
haematopoietic stromal cells may play extensive roles in growth, proliferation, survival and 
maintenance of normal haematopoietic cells. 
 
In contrast to the present belief that the tumor development and progression is a cell 
autonomous process and solely depends on genetic and epigenetic features of tumor cells, 
recent published data indicate that the microenvironment plays a profound influence on 
tumor cells and their malignant features. Moreover, it has been shown that in case of both 
chronic myeloid leukaemia and AML are associated with change in composition of stromal 
compartment (Mayani, 1996). This has been suggested in previous studies, in which stromal 
cells were shown to prevent spontaneous or induced apoptosis in AML cells (Bendall et al., 
1998). Coculturing on the bone marrow-derived MS-5 stromal cell line can rescue the PML 
cell lines NB4 and HL60 from apoptosis by stroma-induced up-regulation of anti-apoptotic 
BCL2 expression in the stroma supported AML cells (Konopleva et al., 2002). These results 
indicate that the stroma cells may play an active role in leukemogenesis and they add 
additional layer to the complex regulatory network controlling tumor development and 
progression. 
 
 
Previous work in the laboratory addressed the hypothesis that the murine embryonic 
microenvironment can induce the differentiation of human tumor cells. To examine such 
interactions, human leukaemic AML cells were injected into pre-implantation murine 
blastocysts at embryonic day 3.5 of gestation. Analysis of developing mice revealed the 
presence of human AML cells in chimeric embryos and adults, albeit at lower frequency, and 
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the appearance of erythroid differentiation markers on progeny of injected human AML cells. 
These chimaeric animals grow and survive normally without succumbing to leukaemia (Durr 
et al., 2003). In contrast, transplantation of leukaemic cells into adult murine recipient 
eventually leads to proliferation of AML blast cells (Henschler et al., 2005). This finding 
strengthens the notion that the embryonic microenvironment is capable of regulating the 
proliferation and differentiation of leukaemic AML cells. 
 
 
In this study, I have investigated the effect of stroma environment on leukaemic cells in vitro. 
For this purpose I have analyzed whether proliferation and differentiation properties of AML 
cells are influenced by direct or indirect coculture with haematopoietic stromal cells from 
embryonic and foetal sources.  Results from the coculture experiments, showed that 
coculture with AGM-derived DAS104-4 cells can induce myeloid differentiation not only in 
established AML cell lines like Kasumi-1or KG-1, but it can also cause primary AML cells 
derived from patient to undergo myeloid differentiation. Whereas other tested murine 
embryo-derived haematopoietic stromal cells like AGM-derived DAS104-8, Yolk sac 
endoderm-derived YSE, yolk sac mesoderm-derived YSM and a foetal liver-derived AFT024 
were ineffective in inducing myeloid differentiation in neither AML cell line or in patient 
derived M2-AML cells. Furthermore cocultivation with DAS104-4 stroma shows upregulation 
of erythroid specific markers such as β-globin and Glycophorin A in the cocultivated KG-1 
cells. These observation support the previously observed results that KG-1 cells  can be 
reprogrammed by murine blastocysts microenvironment which leads to predominantly 
erythroid differentiation of KG-1 cells. These observation further implicate the spectrum of 
stroma environment effect can be context specific i.e., depending on the nature of AML cells.  
 
Further, coculture experiments with direct and transwell coculture of AML cells on DAS104-4 
showed that only directly cocultured Kasumi-1 cells showed the immunophenotype of 
differentiated myeloid cells. Kasumi-1 cells indirectly cocultured with DAS104-4 showed no 
sign of myeloid differentiation. In indirect coculture, AML cells and stroma cells were 
separated by 0.4µm transmembrane, by which any cell-cell interaction between stroma and 
AML cells was avoided, allowing only soluble factors to diffuse through the membrane. 
Therefore, it can be interpreted that direct cell-to-cell contact is essential for DAS104-4 
induced differentiation of Kasumi-1 cells. 
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Comparing proliferation rate of Kasumi-1 cells either cultured without stromal cells or directly 
cocultured on DAS104-4 or NIH3T3 showed that upon direct cocultivation on DAS104-4, 
Kasumi-1 cells shows reduction in proliferation, whereas Kasumi-1 cells cocultured on 
NIH3T3 show similar rate of proliferation as Kasumi-1 cells cultured without any stromal cells. 
These results indicate that DAS104-4 stroma environment has specific proliferation reduction 
activity on Kasumi-1 cells. Similar results were observed when the number of Kasumi-1 cells 
was counted on the basis of trypan blue exclusion microscopy after they were either simply 
cultured without stroma or directly cocultured either on DAS104-4 or AFT024 or NIH3T3. 
Kasumi-1 cell counts cocultured on either NIH3T3 or AFT024 did not show significant 
variation than the Kasumi-1 cells cultured without any stroma. In contrast, there was 
significant reduction in the Kasumi-1 cell count compared to non-cocultured control, when 
they were cocultured on DAS104-4. Further, cell cycle analysis of the cells directly cocultured 
on DAS104-4 for 3 days showed accumulation of cells in G1 phase compared to the non-
cocultured Kasumi-1 cells. In summary, DAS104-4 environment reduces the proliferation of 
Kasumi-1 cells. Interestingly, comparison among proliferation rates of Kasumi-1 cells directly 
cocultivated on DAS104-4 feeder or transwell separated coculture or the coculture 
experiment when the DAS104-4 stroma layer was fixed with 2% PFA showed that for 
maximum AML proliferation reduction activity, direct stroma-AML contact is needed. Our 
observation is analogously consistent with the previous report showing that the normal 
haematopoietic progenitor cells cultured physically separated from stroma in a transwell plate 
shows higher proliferation than the progenitor with direct stroma contact (Hurley et al., 1995). 
Therefore, for most efficient AML proliferation reduction, direct contact with the metabolically 
active stroma is an important requisite.   
 
Complementing to the AML cell proliferation reduction ability, the direct coculture on 
DAS104-4 cells also showed reduction of colony forming cells from the population pool of 
Kasumi-1 cells. In contrast, the Kasumi-1 cells directly cocultured on NIH3T3 or AFT024 
showed similar levels of CFCs compared to the Kasumi-1 cells cultured without any stromal 
cells. This is a very interesting observation as the colony forming cells on semisolid medium 
are the cells that really drive the population. Therefore, DAS104-4 stroma-induced reduction 
in Kasumi-1 CFCs indicates towards stroma-induced reduction in tumorigenic potential of 
Kasumi-1 cells. 
  
                                                                 Discussion 
 
 
 
60 
To focus more light on molecular consequences and the governing mechanism of coculture-
induced effect on AML cells, we compared and quantitated transcript levels of some 
important myeloid specific transcription factors and cell cycle regulatory genes. Quantitative 
RT-PCR analysis indicated that there is coculture-induced up-regulation of transcription 
factors such as CCAAT/enhancer binding protein alpha (C/EBPα) and ETS family 
transcription factor PU.1. Previously, it has been shown that both of these transcription 
factors are crucial for myeloid differentiation. The murine hypomorphs for these transcription 
factors are spontaneously affected with myeloproliferative disorder (Mueller et al., 2002). 
Moreover, it has been shown that other than working as a transcription factor, C/EBPα can 
physically interact with crucial cell cycle regulatory kinases like CDK2 and CDK4 and 
promotes cell cycle check point block. Therefore, we find an indirect correlation that perhaps 
up-regulation of PU.1 and C/EBPα may be the important event during DAS104-4 coculture-
induced reduction in proliferation, G1 phase accumulation and differentiation of Kasumi-1 
cells. The comparative analyses of crucial cell cycle regulatory genes like p16 and p21 show 
DAS104-4 coculture-induced up-regulation in transcript levels, again this is consistent with 
the observed coculture-induced reduction in proliferation of Kasumi-1 cells that we have 
discussed above. 
 
Often AML cells carry chromosomal aberrations like translocations. The t(8:21) type of 
translocation is one of the prevalent genetic aberration among FAB class M2 – the most 
predominant class among all AML classes (Lowenberg et al., 1999). The t(8:21) translocation 
generates the leukaemic AML1-ETO fusion gene which is associated with 10-15% of all de 
novo cases of AML (Heidenreich et al., 2003). This translocation event leads to fusion of the 
acute myeloid Leukaemia-1 (AML1, RUNX1) transcription factor gene located at 
chromosome 21 to the eight twenty-one (ETO, MTG8, CBF2T1) and joins the DNA binding 
part of AML1 to the ETO co-repressor. This leads to conversion of a transcriptional activator 
of definite haematopoiesis into a constitutive and transdominant transcriptional repressor. 
The importance of the AML1-ETO is indicated in the observation that AML1-ETO down-
regulation in an AML cell line renders it sensitive to the differentiation inducing agents. Pabst 
et al. (2001) demonstrated that the AML1-ETO fusion protein suppresses C/EBPα 
expression. The myeloid transcription factor C/EBPα is crucial for normal granulopoiesis, and 
dominant-negative mutations of the C/EBPα gene are found in a significant proportion of 
patients with myeloblastic subtypes (M1 and M2) of AML. Analysis of AML1-ETO transcript 
levels in Kasumi-1 cells either cultured alone or cocultured either on DAS104-4 or NIH3T3 or 
AFT024 reveals down-regulation of AML1-ETO transcript in DAS104-4 cocultured Kasumi-1 
cells. Whereas, there is no difference between AML1-ETO transcript levels of non-cocultured 
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cells or cells cocultivated either on NIH3T3 or AFT024 cells. Further analyses of Kasumi-1 
cells, directly or indirectly cocultured on DAS104-4, display stroma contact-dependent 
decrease in AML1-ETO transcript level, which correlate well with the functional data such as 
stroma contact-dependent myeloid differentiation of the Kasumi-1 cells.  
 
From the previous studies, it has been shown (Charrad et al., 1999) that many AML primary 
and established cell lines can be induced to differentiate by activation of CD44 receptor by 
ligating antibodies. And even in vivo administration of CD44 ligating antibodies to the non-
obese diabetic-severe combined immuno-deficient (NOD-SCID) mice transplanted with 
human AML showed marked reduction in leukaemic repopulation. As staining for CD44 
showed that all three AML cell lines i.e., Kasumi-1, KG-1 and NB4 show positive staining for 
CD44 receptor on the surface, further it was interesting to see if the activation of CD44 is just 
the underlying mechanism for the DAS104-4 environment-induced myeloid differentiation of 
Kasumi-1 cells. However, my result indicated that DAS104-4 induced differentiation is 
independent of CD44 activation. Hence, the embryonic stromal environment may provide an 
alternative means to differentiate human AML cells.  
  
To understand the possible role of AML1-ETO transcription down-regulation in coculture-
induced effect on AML cells, transcription from AML1-ETO gene was knocked down and the 
consequences were analyzed. Upon siRNA mediated knockdown of AML1-ETO gene 
expression alone, Kasumi-1 cells showed lower rate of proliferation, together with decrease 
in colony forming cells. However, knocking down the expression of AML1-ETO alone by itself 
was not found to be sufficient for myeloid differentiation. However, in combination with 
DAS104-4 cocultivation, siRNA mediated AML1-ETO knock down compared to the cells 
transfected with control siRNA showed additive effect on coculture mediated Kasumi-1 
myeloid differentiation. This indicates that AML1-ETO down-regulation may have an active 
role on the coculture-induced effect but in addition to AML1-ETO down-regulation further 
stimuli are required for the coculture-induced myeloid differentiation in the AML cells. 
 
The concept emerging from this study indicates that the stroma environment can affect 
leukaemic cell proliferation and differentiation. In the present scenario, stroma may elicit 
atleast two different signals to the responding leukaemic cells: One soluble signal that can 
diffuse through the transwell membrane and causing reduction in proliferation without having 
any direct effect on differentiation and second signal that is cell contact-dependent and which 
can account for both differentiation induction and cell proliferation reduction. The results 
described here add a new prospective to our understanding of interaction between leukaemic 
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cells and its environment. Furthermore, this study encourages further investigation into the 
mechanistic details of molecular and cellular interaction between the leukaemic cells and 
their stroma, which in turn may lead to the identification of new paradigm for active control 
and reprogramming of human leukaemic cells. 
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6. MATERIALS AND METHODS 
6.1 Materials 
6.1.1 Antibodies 
 
6.1.1.1 Primary antibodies 
Specificity Clone Isotype Conjugate Supplier 
β−Actin I-19 IgG1 HRP Santa Cruz 
CD117 (c-kit) 3H389 IgG1 FITC United States Biologicals 
CD11b 44 IgG1 FITC Cymbus Biotech 
CD14 2D-15C IgG1 FITC, Biotin Chemicon 
CD15 ZC-18C IgM FITC Chemicon 
CD235a YTH89.1 RAT IgG2b 
no 
conjugate DPC Biermann 
CD38 T16 IgG1 FITC Immunotech 
CD44 A3D8 IgG1 no conjugate Sigma-Aldrich 
CD45 HI30 IgG1, κ FITC BD Bioscience 
ETO C-20 IgG1 no conjugate Santa Cruz Biotech 
Mouse CD16/CD32 2.4G2 IgG2a, κ no conjugate BD Bioscience/made in lab 
Mouse IgG1 isotype 
control - IgG1 FITC Chemicon 
 
 
 
6.1.1.2 Secondary antibodies 
Specificity Host Conjugate Supplier 
Goat Cow HRP Dianova 
Mouse Goat Cy3 Chemicon 
Rat Goat FITC Dianova 
 
 
 
6.1.1.3 Conjugate for antibody 
Conjugate Supplier 
Strptavidin-FITC BD Bioscience 
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6.1.2 Cell culture related materials 
 
10% BSA in Iscove´s MDM StemCell Technologies Inc 
ATRA Sigma-Aldrich 
β-Mercaptoethanol Merck 
Bovine serum albumin                                                               Boeringer Mannheim 
Dulbecco´s MEM GibcoBRL 
Foetal calf serum                                                Biochrom KG 
Ficoll                                                                                    Sigma-Aldrich 
IL-3                                                                                          Stem Cell Techologies Inc 
Iscove´s MDM GibcoBRL 
L-Glutamine                                                               GibcoBRL 
MethoCult™ M3134                                                        StemCell Technologies Inc 
Non-essential amino acids                                         GibcoBRL 
Penicillin/Streptomycin                                                            GibcoBRL 
RPMI 1640                                                                              PAA 
Sodium pyruvate GibcoBRL 
Streptomycin                                                                           Sigma-Aldrich 
Trypsin-EDTA (1X)                                                             GibcoBRL 
 
6.1.3 Consumables 
3mm-Whatman paper Scheicher & Schüll 
Cell sieve BD, Falcon 
Cover slip Hartenstein 
Disposable gloves Kimberly-Clark 
FACS tubes Elkay, Greiner 
Filter cup Nalgene 
Nitrocellulose membrane Scheicher & Schüll 
Pipette tips University store 
Plastic material for cell culture Falcon, Greiner, Nunc, Sarstedt 
Scalpel Ratiomed 
Sterile filter Schleicher & Schüll 
Super-Frost® Plus slide Menzel-Gläser 
Syringes Braun, Dispomed 
X-ray film Fuji, Sigma-Aldrich 
 
6.1.4 Chemicals 
 
4´,6-Diamidin-2-phenylindol (DAPI) Sigma-Aldrich 
7-AAD Sigma-Aldrich 
Acetic acid Applichem 
Actinomycin D (AD) Sigma-Aldrich 
Agarose NEEO (Ultra Quality)                    Roth AG 
Ammonium persulfate (APS) Sigma-Aldrich 
Blocking milk powder Roth 
Boric acid Applichem 
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Bovine serum albumin                                                               Boeringer Mannheim 
CFSE Molecular Probes 
Dextran T500 Roth 
Diff-Quik® Dade Behring 
Dithiotreitol (DTT) Applichem 
DMSO Sigma-Aldrich 
DNA size marker MBI Fermentas 
EDTA                                                                               Applichem 
Ethanol Applichem 
Ethidium bromide Merck 
Gelatin Sigma-Aldrich 
Glycerol Applichem 
HCl, 37%                                                                                 Applichem 
Hepes                                                                                      Sigma 
Isopropanol                                                                          Applichem 
Methanol Sigma-Aldrich 
Mounting medium                                  DAKO corporation 
N,N,N´,N´-Tetramethylendiamin (TEMED) Sigma-Aldrich 
Para formaldehyde (PFA) Applichem 
Phenol-Chloroform-Isoamyl alcohol                                                          Applichem
Potassium chloride                                                                 Applichem 
Protein size marker MBI Fermentas 
Rotiphorese® Gel 30 Roth 
SDS Sigma-Aldrich 
Sodium azide Applichem 
Sodium borate                                                                         Applichem 
Sodium chloride Applichem 
Sodium citrate                                                                     Applichem 
Sodium hydroxide                                                                                   Applichem 
SYBR green mix Fynnzyme 
Tris Applichem 
Triton® X-100 GibcoBRL 
Trypan blue Sigma-Aldrich 
Tween 20 Applichem 
Water Ultra pure                                                                          Merck 
Xylol Applichem 
 
6.1.5 Instruments 
 
Agarose gel cast MSZ workshop 
Cell freezing container Nalgene 
Centrifuge Hettich, Eppendorf, Sorvall 
CytoSpin ThermoShandon 
Digital camera Olympus 
Digital weighing balance Sartorius 
Film developer machine Agfa 
Flow cytometer Becton Dickinson 
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Gamma ray irradiation Central facility MSZ 
Gel and blotting chamber BioRad 
Incubator Forma Scientific 
Inverted microscope Zeiss 
Neubauer chamber Marienfeld 
pH-Meter Knick 
Photometer Eppendorf 
Real Time PCR Gene Rotor 
Sterile bench Heraeus 
T3 Thermocycler Biometra 
Vortexer Scientific Industries 
Water bath GFL 
 
 
6.2 Cell culture 
6.2.1 AML and stromal cells and their maintenance 
 
Human leukaemic Kasumi-1 (DSMZ, Braunschweig, Germany) (Asou et al., 1991);  KG-1 
(DSMZ, Braunschweig, Germany) (Koeffler et al., 1981); EOL-1 (Saito et al., 1985) and NB-4 
cells (Lanotte et al., 1991) and murine stromal cells AFT 024 (Moore et al., 1997); DAS 104-4 
(Ohneda et al., 1998) and DAS 104-8 (Ohneda et al., 1998), YSE and YSM (Yoder et al., 
1995) were expanded in RPMI 1640 (PAA) in the presence of 20% FCS, penicillin 
100units/ml, streptomycin 100µg/ml and 10mM 2-ME. Cells were cultured in a humidified 
37°C incubator with 5% CO2. Primary M2-AML cells were kindly provided by Prof. Reinhard 
Henschler (Institute for transfusion medicine and immuno-haematology, University of 
Frankfurt). Patient-derived primary AML cells are originating from a 70 year-old male patient 
with FAB M2 AML and derived observing approved institutional procedures for obtaining 
informed consent according to the declaration of Helsinki (Ethics Committee, Medical 
Faculty, University of Frankfurt, Germany). The primary AML cells were expanded in the cell 
culture medium, RPMI 1640 (PAA), in the presence of 20% FCS, penicillin 100units/ml, 
streptomycin 100µg/ml and 10mM 2-ME. 
 
6.2.2 Passaging of Stromal cell lines 
 
Stromal cell lines proliferate very well and must be passaged every 3-4 days. 70-80% 
confluence is the best and before adding 1ml of 1X Trypsin-EDTA (Gibco) to dislodge the 
stromal cells from the plates, stromal monolayer is washed once by 1X PBS. Then 5ml of the 
medium is added followed by flushing of cells in and out by 5ml pipette 3-4 times to ensure 
that the cells are not clumped before plating. 
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6.2.3 Freezing of AML and Stromal cell lines 
 
1. Spin down the cells at 200xg (RCF) for 10 min, RT 
2. Resuspend in 90% foetal calf serum and 10% dimethylsulphoxide (DMSO) 
3. Freeze 2x106/ml (min - 1x106/ml; max - 5x106/ml), approximately 1.8ml/vial 
4. Freeze in a freezing box with isopropanol at -70°C overnight 
5. Next day put the vials in liquid nitrogen 
 
6.2.4 Thawing of AML and Stromal cell lines from liquid nitrogen storage 
 
1. Put the vial into a water bath at 37°C for a short time (1min) 
2. Pour the cells into a 50ml Falcon tube in the laminar flow hood 
3. Dilute slowly by adding 10ml complete medium drop wise over 10min 
4. Leave the cells for 10min in the laminar flow hood 
5. Spin them down at 200xg, 10min, RT 
6. Pour off the supernatant 
7. Resuspend the pellet in 5ml complete medium 
8. Pour into T25 Falcon culture flask, leave in the incubator (5% CO2, 98% humidity, 37°C) 
overnight 
 
6.2.5 Removing of dead AML and Stromal cell lines cells 
 
1. Count the living cells the day after thawing in the 5ml culture 
2. Pour Histopaque™ in a sterile tube under the hood 
3. Drop 5ml of cell suspension over Histopaque™, carefully, do not disturb the interface 
4. Spin down at 400xg (RCF), 30min, RT 
5. The live cells accumulate at the interface while the dead cells sink to the bottom 
6. Collect the cells off the interface (take 5ml of cell suspension plus 1ml 
interface/Histopaque™) into a 15ml Falcon tube which contains 5ml of medium 
7. Spin down again at 200xg (RCF), 10min, RT 
8. Pour off the supernatant and resuspend the pellet at 8x104/ml cells in medium 
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6.3 Coculture 
6.3.1 Feeder preparation and direct coculture 
 
Stromal cells are grown to the log phase by splitting them one day before irradiation. For 
irradiation, cells are trypsinized and counted; 2-5x106 cells are suspended in 1 ml of cell 
culture medium and irradiated at 40Gy (single dose, 137Cs-Gammatron, 0.511MeV, dose 
rate=1.7Gray/min). After irradiation, cells are plated to confluence. On the next day, 5x105 
leukaemic cells are seeded directly onto stromal cells and cocultivated for given period of 
time (Figure 32). Cocultured leukaemic cells are harvested by mild washes with culture 
medium. The recovery rate of cocultured leukaemic cells was in the range of 60-80% as 
analyzed by microscopy using the cell size difference between leukaemic and stromal cells 
as parameter. 
 
 
 
Figure 32. Sketch showing directly cocultured AML cells on irradiated feeder monolayer. 3x105 γ-
irradiated cells (40Gy) are seeded in each well of 6 well polystyrene tissue culture plate (Greiner 
bio-one) and incubated for overnight in the incubator (5% CO2, 98% humidity, 37°C) to make 
stromal monolayer with >80% confluence. On the following day, the old medium is aspirated and 
3ml/well fresh medium with 5x105 AML cells are seeded directly on the stromal monolayer. 
 
 
 
6.3.2 Indirect coculture 
 
Exponentially growing stromal cells are irradiated with 40Gy. After irradiation, cells are plated 
to confluence. 0.4µm pore size transwell insets (Costar) are used for indirect coculture. 
Transwell insets are placed gently on the wells with irradiated confluent stroma and the 5x105 
leukaemic cells are seeded on the transwell (Figure 33). Cocultured leukaemic cells are 
harvested by mild washing of transmembrane inset with culture medium.  
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Figure 33. Sketch showing indirect cocultured AML cells on irradiated feeder monolayer. 3x105  
γ-irradiated cells are seeded in each well of 6 well tissue culture plate (Greiner bio-one) and 
incubated overnight in the incubator (5% CO2, 98% humidity, 37°C) to make stromal monolayer 
with >80% confluence. On the following day, the old medium is aspirated and fresh 1ml/well 
medium is gently placed over the monolayer. Subsequently, polystyrene transwell insets with 
0.4µm pore size polycarbonate membrane (Costar) are placed gently over the well. Finally, 5x105 
AML cells suspended in 2ml medium are gently placed on the membrane.  
 
6.3.3 Coculture on fixed stroma 
 
Stroma cells are irradiated with 40Gy and seeded till next morning to form confluent layer. 
The stromal monolayer is washed twice with 1X PBS before treating with 2% PFA in 1X PBS 
for 5 minutes. Later, the monolayer is washed 5 times with PBS to remove any trace of fixing 
solution before seeding 5x105 leukaemic cells for coculture (Figure 34). Cocultured 
leukaemic cells are harvested by mild washes with culture medium. The recovery rate of 
cocultured leukaemic cells was in the range of >80% as analyzed by microscopy using the 
cell size difference between leukaemic and stromal cells as parameter. 
 
  
 
Figure 34. Sketch showing directly cocultured AML cells on irradiated fixed feeder monolayer. 
3x105  γ-irradiated cells (40Gy) are seeded in each well of 6 well polystyrene tissue culture plate 
(Greiner bio-one) and incubated for overnight in the incubator (5% CO2, 98% humidity, 37°C) to 
make stromal monolayer with >80% confluence. On the following day, the old medium is 
aspirated followed by overlaying the monolayer with 3ml of fixing solution (2% PFA in 1X PBS). 
After incubation at room temperature for 10 min, the fixing solution is aspirated followed by five 
rounds of washing with 1X PBS to remove any trace of fixative agent. Finally, 3ml/well fresh 
medium with 5x105 AML cells are seeded directly on the fixed stromal monolayer. 
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6.4 Flowcytometry  
 
For immunophenotyping by flowcytometry, 2x105 cultured cells are washed with FACS buffer 
(PBS, 0.4% BSA, 0.02% NaN3, pH 7.4). After blocking of Fc receptors (FcgRII/III) with 2.4G2 
antibody, cells are incubated with appropriate antibodies for 30min at 4°C. The following 
antibodies were used: IgGa isotype-FITC control (Chemicon), CD11b-FITC (Chemicon) and 
CD14-FITC (Chemicon). To visualize dead cells, 10µg/ml propidium Iodide (PI) (Sigma) is 
added and 10,000 PI-negative, living cells are acquired on a FACSCalibur. 
  
6.5 Immuno-cytochemistry and morphological analysis 
 
Immuno-cytochemistry is performed in the laboratory of Prof. Axel Greiner (Heidelberg) on 
cytospins, fixed with acetone for 10min at room temperature and air dried (Greiner et al., 
1997). Slides are incubated for 20min with 0.03% H2O2/PBS to inactivate endogenous 
peroxidase, followed by a blocking step with 10% horse serum/PBS for 20min at room 
temperature. The specific antibody (PGM1, DAKO) is diluted in 10% horse serum/PBS at a 
final concentration of 36µg/ml and added for 30min. For immuno-cytochemical detection, 
slides are incubated with a peroxidase-coupled rabbit anti-mouse antibody (DAKO) for 30min. 
The peroxidase was displayed using the Sigma Fast diaminobenzidine peroxidase substrate 
tablet set (Sigma). For morphological analysis of cocultured cells, 2x105 cells were cytospun. 
Myeloid differentiation was quantified by Pappenheim staining (Chuang and Li, 1997).  
 
 
 
6.6 CFSE staining 
 
CFSE (5- and 6-carboxyfluorescein diacetate succinimidyl ester) is a fluorescein derivative 
that is cell permeable and non-fluorescent. The cleavage of the acetate groups by 
intracellular esterase renders the molecule fluorescent, and the attachment of the fluorescein 
group to all intracellular proteins via aminolysis of the succinimidyl ester ensures that the dye 
is retained within the cells (Figure 35A). As the cells divide, CFSE is distributed between the 
daughter cells (Lyons and Parish, 1994). Using flowcytometry, the rate of cell proliferation 
can be correlated with the rate of fluorescence loss (Figure 35B).  For labelling the Kasumi-1 
cells with CFSE, 5-10x106 Kasumi-1 cells are incubated for 8min at RT in 5µM CFSE solution 
(Molecular Probes). Further dye uptake is prevented and unincorporated CFSE is 
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sequestered and washed by adding excess RPMI medium/20% FCS. Prior to culturing, 
traces of unbound CFSE are removed by intensive washes of cells in RPMI medium/20% 
FCS.   After growth for overnight, the cells are seeded for coculture on the following day. 
After coculture, cells are harvested and CFSE fluorescence is assayed on a FACSCalibur 
(Becton Dickinson). 
 
 
 
Figure 35. CFSE retention assay. (A) Showing scheme of CFSE incorporation and 
fluorescent labelling of intracellular proteins. (B) Showing an experiment where Kasumi-1 
cells were labelled with CFSE and subsequently allowed to divide in optimum cell culture 
conditions, flowcytometric analysis of the CFSE labelled cells on subsequent days shows 
sequential reduction in fluorescence of Kasumi-1 cells. 
 
 
6.7 Methyl cellulose colony forming assay 
This method quantifies the amount of early progenitor cells in the total cell pool. The colony 
starting cells on semisolid medium are known as colony forming cells (CFCs). The semisolid 
methyl cellulose medium is based on IMDM medium with following components  
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- 40% v/v MethoCult™ M3134 
- 30% v/v FCS 
- 1% w/v BSA 
- 100U/ml Penicillin/Streptomycin 
- 2mM L-Glutamine 
- 1x10-4M β-Mercaptoethanol 
The semisolid medium is made and aliquoted in 15ml conical bottom tubes, special care is 
taken to avoid introduction of air bubbles. AML cells are counted and 1.5x104 trypan blue-
negative AML cells are suspended in 300µl of IMDM medium and added to the aliquoted 
2.7ml MC medium, followed by mixing by vortexing to have even cell suspension. In doublet, 
1ml MC cell suspension mix is plated carefully, without introducing any bubbles, on 36mm 
cell culture dishes. The plates are incubated in incubator (37°C, 5% CO2 and 100% humidity) 
 
 
6.8 Cell cycle analyses 
One million cells are washed with FACS buffer, resuspended and incubated in PI staining 
solution containing 1.6% sodium citrate (Applichem), 0.04% Triton X-100 (BioChemika) and 
0.1% PI (Sigma) and 20µg/ml RNAse (Sigma) for 10min followed by washing and 
suspending in FACS buffer.  PI labelling is assayed with a FACSCalibur. The total DNA 
content is plotted as a function of PI-area. The Cylchred software version 1.0.2, based on 
algorithms by Watson et al. (Watson et al., 1987), is used to determine cell cycle status. 
 
6.9 RNA and DNA isolation 
 
6.9.1 Isolation of DNA 
 
1. Put the tissue or cells in 700µl of lysis buffer with proteinase K 
2. Incubate over night (o/n) at 56°C in the rotation incubator 
3. Add 7µl of RNAse to degrade RNA 
4. Incubate for 30min at 37°C 
5. Add an equal volume of Phenol-Chloroform, shake for 5min 
6. Centrifuge for 10min at 20000xg (10000rpm) 
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7. Transfer supernatant to another tube; hydrophilic DNA is in aqueous phase of supernatant, 
while the proteins are in the interphase 
8. Add an equal volume of phenol/chloroform to the water phase, shake for 5 min 
9. Centrifuge for 10min at 10000rpm 
10. Transfer the supernatant to a new tube 
11. Add an equal volume of isopropanol to the water phase, shake 
12. Incubate for 20min at -20°C 
13. Centrifuge for 10min at 20000xg (14000rpm); DNA will be visible as a white pellet at the 
bottom of the tube 
14. Remove supernatant and add 700µl of 70% ethanol (washing of DNA) 
15. Vortex to dissolve the pellet 
16. Centrifuge for 20min at 20000xg 
17. Remove supernatant and add 700µl of 70% ethanol 
18. Centrifuge for 20min at 20000xg 
19. Remove ethanol and dry the DNA 
20. Dissolve DNA pellet in ddH2O 
 
Measurement of DNA concentration 
The aromatic rings of purine and pyrimidine bases of nucleic acids dissolved in water absorb 
the light at 260nm wave length. The concentration of DNA and optical density at 260nm 
(OD260) are in linear relationship so it is possible to calculate the concentration with very 
simple formula: 
C= OD260x 50µg/ml double stranded DNA 
C= OD260x 40µg/ml single stranded DNA 
C= OD260x 33µg/ml single stranded RNA 
Bio Photometer (Eppendorf) is used for measuring of DNA concentration. 
 
6.9.2 RNA isolation and RT-PCR 
 
Wash 1 million cells once in PBS and pellet by centrifuging for 10 minutes at 5000xg 
(3500rpm). 
Resuspend the cell pellet in 700µl of RNA peq gold, mix by gentle pipetting 
Add 100µl of chloroform, mix by gentle vortexing 
Centrifuge for 10min at 20000xg (14000rpm) 
Transfer the aqueous supernatant to fresh tube 
Add equal volume of isopropanol to the aqueous phase and mix gently by inverting. 
Precipitate nucleic acid at -20°C for 20 minute 
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Centrifuge for 10min at 20000xg (14000 rpm) 
Discard the supernatant and resuspend the pellet in 1ml of 70% Ethanol. 
Centrifuge for 10min at 20000xg (14000 rpm) 
Discard the supernatant and again resuspend the pellet with 1ml of ethanol for second wash 
Centrifuge for 10min at 20000xg (14000 rpm) 
Decant the supernatant and suspend the pellet in 20µl DEPC-treated water 
Bio Photometer (Eppendorf) is used for quantitation of RNA 
 
 
 
6.9.2.1 DNAse treatment 
 
To remove the contaminating genomic DNA from the total RNA, the RNA sample is treated 
with RNAse free recombinant DNAse by the following method: 
 
Mix 1µg of RNA with 1.3µl of 10X DNAse buffer (Ambion) and add DEPC treated water to 
12µl, finally add 1µl (2U) of DNAse (Ambion) 
Incubate for 30 minute at 37°C 
Stop reaction by adding 1µl of 25mM EDTA, 10min inactivation at 65°C. 
Half of the reaction mix containing 0.5µg RNA is used for cDNA synthesis and half for 
“no reverse transcription control” 
 
6.9.2.2 First strand synthesis 
 
Reverse transcription reaction to synthesize first cDNA strand  from DNAse treated total RNA 
include 0.5µg of RNA in 6.5µl volume, 1µl (200ng) of oligo d-T (16-mer) and 5µl of DEPC 
treated water, the total mix is heated at 65°C for 5 minutes to resolve all secondary RNA 
structures. Then 1µl of dNTPs (10mM), 4µl of 5X first strand synthesis buffer, 2µl of 100mM 
DTT and 0.5µl of M-MLV (Invitrogen) are added to make final 20µl mixture, incubation for 1hr 
at 37°C. 
cDNAs are then stored at -20°C.     
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6.9.2.3 Polymerase chain reaction (PCR) 
 
The amplification of specific DNA fragments is performed in T3 Thermoblock (Biometra, 
Goettingen). Total cDNA is used as template. All the oligonucleotides (primers) are 
synthesized by MWG Biotech. 
 
 
Human β−Actin PCR 
 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5´-AGCCTCGCCTTTGCCGA-3´) 
200ng antisense primer (5´-CTGGTGCCTGGGGCG-3´) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 30sec 
60°C 30sec 36 cycles 
72°C 90sec 
72°C 2min 1 cycle 
Fragment size: 180bp 
 
Primer sequences for PCR are taken from literature (Kreuzer et al., 1999) 
 
 
AML1-ETO PCR 
 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5’- AGCTTCACTCTGACCATCAC -3’) 
200ng antisense primer (5’- TCAGCCTAGATTGCGTCTTC -3’) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl  
Materials & Methods 
 
76 
 
95°C 5min 1 cycle 
95°C 60sec 
60°C 30sec 35 cycles 
72°C 35sec 
72°C 2min 1 cycle 
Fragment size: 200bp 
Primer sequences for PCR are taken from literature (Mrozek et al., 2001) 
 
 
 
C/EBPα PCR 
 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5’-GGGCCAGGTCACATTTGTAAA-3’) 
200ng antisense primer (5’-AGTAAGTCACCCCCTTAGGGTAAGA-3’) 
0.15µl Super Taq Polymerase (5U/µl) 
200ng DNA 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 10sec 
60°C 30sec 32 cycles 
72°C 35sec 
72°C 2min 1 cycle 
Fragment size: 110bp 
Primer sequences for PCR are taken from literature (Ishiyama et al., 2003) 
 
 
β-globin PCR 
 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
Materials & Methods 
 
77 
200ng sense primer (5’-GAGAAGTCTGCCGTTACTGCC-3’) 
200ng antisense primer (5’- CCGAGCACTTTCTTGCCATGA-3’) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 30sec 
60°C 60sec 35 cycles 
72°C 60sec 
72°C 2min 1 cycle 
Fragment size: 188bp 
Primer sequences for PCR for forward primer is same as the coding sequence between 22-
47 of the ORF and reverse primer corresponds to 209-189 of the coding sequence. 
 
p14 ARF PCR 
 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5’- AGCAGCCGCTTCCTAGAAGAC -3’) 
200ng antisense primer (5’-CACGGGTCGGGTGAGAGT-3’) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 30sec 
60°C 60sec 40 cycles 
72°C 60sec 
72°C 2min 1 cycle 
Fragment size: 119bp 
Primer sequences for PCR are taken from literature (Linggi et al., 2002) 
 
p16 (INK4A) 
 
PCR reaction: 
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5µl 10x PCR buffer 
2µl dNTPs (2.5mM each) 
200ng sense primer (5’-tggacctggctgaggagct-3’) 
200ng antisense primer (5’-gaccttccgcggcatctat-3’) 
0.15µl Super Taq Polymerase (5U/µl) 
add till 50µl ddH2O 
95°C 5min 1 cycle 
95°C 30 sec 
60°C 60 sec 40 cycles 
72°C 60 sec 
72°C 2min 1 cycle 
Fragment size: 108 
Primer sequences for PCR are taken from literature (Linggi et al., 2002) 
 
 
p21 (WAF1) PCR 
 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5’-GGACAGCAGAGGAAGACCATGT-3’) 
200ng antisense primer (5’-TGGAGTGGTAGAAATCTGTCATGC-3’) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 10sec 
60°C 30sec 35 cycles 
72°C 35sec 
72°C 2min 1 cycle 
Fragment size: 150bp 
Primer sequences for PCR are taken from literature (Koga et al., 2003) 
 
 
PU.1 PCR 
PCR reaction: 
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5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5’--3’) 
200ng antisense primer (5’--3’) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 10sec 
60°C 30sec 40 cycles 
72°C 35sec 
72°C 2min 1 cycle 
Fragment size: 86bp 
Primer sequences for PCR are taken from literature (Walter et al., 2005) 
 
 
RUNX1 PCR 
PCR reaction: 
5µl 10X PCR buffer 
1µl dNTPs (2.5mM each) 
200ng sense primer (5’-CCCACCGTGGTCCTACGAT-3’) 
200ng antisense primer (5’-CTGGCACGTCCAGGTGAAA-3’) 
0.15µl Super Taq Polymerase (5U/µl) 
 
Add ddH2O up to 50µl 
 
95°C 5min 1 cycle 
95°C 10sec 
60°C 30sec 40 cycles 
72°C 35sec 
72°C 2min 1 cycle 
Fragment size: 96bp 
Primer sequences for PCR are taken from literature (Mikhail et al., 2002) 
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6.9.3 Quantitative RT-PCR 
 
cDNA is amplified using Rotor-Gene RG-300 (Corbett Research) with SYBR Green mix 
(Fynnzyme). For touch-down PCR, the primer annealing temperature is decreased from 
65°C to 60°C (0.5°C/cycle), denaturation is at 95°C and extension at 72°C for 10 cycles, 
followed by 35 cycles at 60°C annealing temperature. SYBR Green analyses are normalized 
to human β-actin gene expression. Sequences of primers are human specific and desribed 
above with individual PCR.  
 
 
6.9.4 Separation of amplicon fragments on agarose gel 
 
The amplified DNA fragments are separated on 1.5% agarose gel. 6gm of agarose is 
dissolved in 400ml of TBE-buffer, cooked in microwave and 20µl of 0.5% ethidium bromide 
solution is added. 10-20µl of PCR product is mixed with 3µl of Bromophenol blue buffer. 
Electrophoretic separation is dependent on fragment size and is performed in electric field of 
5-8V/cm for 30-60 min. Ethidium bromide incorporates between nucleic acids and 
visualisation is possible at 560nm on UV light. Standard size of markers is compared with 
separated PCR products. 
 
Markers: pTZ plasmid digested with restriction enzyme HinfI and pSM with Hind III. DNA 
fragments of pTZ-HinfI have size from 44 to 1202bp, and that of pSM-HindIII between 145 
and 3440bp. 
 
 
6.10 siRNA studies 
 
0.75-8x106 Kasumi-1 cells are grown to log phase and are transfected with 120nmol of either 
AML1-ETO siRNA (MWG) (Heidenreich et al., 2003) or control siRNA (Santa Cruz Biotech) 
using Tranfectin™ (Biorad). The number of fluorescently stained cells is determined by 
flowcytometry (FACSCalibur) at 24hr post- transfection using FAM-labelled siRNA against 
AML1-ETO. Flowcytometry provides quantification of transfection efficiency directly as a 
percent of positively-fluorescent cells. Sequences of siRNAs are:  
AML1-ETO siRNA (5´-[CCUCGAAAUCGUACUGAGA]RNA [TT]DNA-3´);  
(3´-[TT]DNA [GGAGCUUUAGCAUGACUCU]RNA-5´);  
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FAM-labelled AML1-ETO siRNA (5´-[FAM]-[CCUCGAAAUCGUACUGAGA]RNA [TT]DNA-3´); 
(3´-[TT]DNA[GGAGCUUUAGCAUGACUCU]RNA-5´) 
 
 
 
 
6.11 Treatment of AML cell lines with CD44-activating antibody 
 
AML cells are seeded in triplicate at a concentration of 2×105 cells/ml in RPMI 1640 (PAA) in 
the presence of 20% FCS, penicillin 100units/ml, streptomycin 100µg/ml and 10mM 2-ME in 
96-well tissue culture plates (Nunc) in a total volume of 150µl/well. AML samples are treated 
for 3 days with CD44-activating monoclonal antibody (A3D8 clone, Sigma) or IgG1 isotype 
control antibody at a final concentration of 20µg/ml as described (Charrad et al., 1999). 
 
 
6.12 Statistical analysis 
 
Student t-test was performed using GraphPad Prism version 3.00 for Windows, GraphPad 
Software, San Diego, California, USA.  
References 
82 
7 REFERENCES 
Ahn, M. Y., Huang, G., Bae, S. C., Wee, H. J., Kim, W. Y., and Ito, Y. (1998). Negative 
regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a 
mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, 
AML1/ETO. Proc Natl Acad Sci U S A 95, 1812-1817. 
Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B., Harada, H., Lenny, N., Downing, J. R., 
Meyers, S., and Hiebert, S. W. (2001). ETO, a target of t(8;21) in acute leukaemia, makes 
distinct contacts with multiple histone deacetylases and binds mSin3A through its 
oligomerization domain. Mol Cell Biol 21, 6470-6483. 
Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., and Kamada, N. (1991). 
Establishment of a human acute myeloid leukaemia cell line (Kasumi-1) with 8;21 
chromosome translocation. Blood 77, 2031-2036. 
Bates, S., Bonetta, L., MacAllan, D., Parry, D., Holder, A., Dickson, C., and Peters, G. (1994). 
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases 
that associate with cyclin D1. Oncogene 9, 71-79. 
Bautch, V. L., Toda, S., Hassell, J. A., and Hanahan, D. (1987). Endothelial cell tumors 
develop in transgenic mice carrying polyoma virus middle T oncogene. Cell 51, 529-537. 
Bendall, L. J., Makrynikola, V., Hutchinson, A., Bianchi, A. C., Bradstock, K. F., and Gottlieb, 
D. J. (1998). Stem cell factor enhances the adhesion of AML cells to fibronectin and 
augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukaemia 12, 1375-
1382. 
Bishop, J. F., Matthews, J. P., Young, G. A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., 
Enno, A., Wolf, M. M., Fox, R., et al. (1996). A randomized study of high-dose cytarabine in 
induction in acute myeloid leukaemia. Blood 87, 1710-1717. 
Blair, A., Hogge, D. E., and Sutherland, H. J. (1998). Most acute myeloid leukaemia 
progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype 
CD34(+)/CD71(-)/HLA-DR. Blood 92, 4325-4335. 
Bodine, D. (1995). Mobilization of peripheral blood 'stem' cells: where there is smoke, is there 
fire? Exp Hematol 23, 293-295. 
References 
83 
Bonifer, C., Faust, N., Geiger, H., and Muller, A. M. (1998). Developmental changes in the 
differentiation capacity of haematopoietic stem cells. Immunol Today 19, 236-241. 
Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukaemia is organized as a 
hierarchy that originates from a primitive haematopoietic cell. Nat Med 3, 730-737. 
Bouabdallah, R., Olive, D., Meyer, P., Lopez, M., Sainty, D., Hirn, M., Mannoni, P., 
Fougereau, E., Gastaut, J. A., and Maraninchi, D. (1998). Anti-GM-CSF monoclonal antibody 
therapy for refractory acute leukaemia. Leuk Lymphoma 30, 539-549. 
Brasel, K., Escobar, S., Anderberg, R., de Vries, P., Gruss, H. J., and Lyman, S. D. (1995). 
Expression of the flt3 receptor and its ligand on haematopoietic cells. Leukaemia 9, 1212-
1218. 
Breitman, T. R., Selonick, S. E., and Collins, S. J. (1980). Induction of differentiation of the 
human promyelocytic leukaemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 
77, 2936-2940. 
Briggs, M., Adams, J. A., Brereton, M. L., Burgess, R., Hyde, K., Lenehan, H., and Yin, J. A. 
(2001). Comparison of megakaryopoiesis in vitro of paired peripheral blood progenitor cells 
and bone marrow harvested during remission in patients with acute myeloid leukaemia. Br J 
Haematol 115, 563-568. 
Brinster, R. L. (1974). The effect of cells transferred into the mouse blastocyst on subsequent 
development. J Exp Med 140, 1049-1056. 
Bruserud, O., Gjertsen, B. T., and Huang, T. (2000). Induction of differentiation and 
apoptosis- a possible strategy in the treatment of adult acute myelogenous leukaemia. 
Oncologist 5, 454-462. 
Burel, S. A., Harakawa, N., Zhou, L., Pabst, T., Tenen, D. G., and Zhang, D. E. (2001). 
Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 
21, 5577-5590. 
Carey, M. (1998). The enhanceosome and transcriptional synergy. Cell 92, 5-8. 
References 
84 
Caron, P. C., Dumont, L., and Scheinberg, D. A. (1998). Supersaturating infusional 
humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukaemia. Clin Cancer 
Res 4, 1421-1428. 
Casasnovas, R. O., Campos, L., Mugneret, F., Charrin, C., Bene, M. C., Garand, R., Favre, 
M., Sartiaux, C., Chaumarel, I., Bernier, M., et al. (1998). Immunophenotypic patterns and 
cytogenetic anomalies in acute non-lymphoblastic leukaemia subtypes: a prospective study 
of 432 patients. Leukaemia 12, 34-43. 
Chang, K. S., Fan, Y. H., Stass, S. A., Estey, E. H., Wang, G., Trujillo, J. M., Erickson, P., 
and Drabkin, H. (1993). Expression of AML1-ETO fusion transcripts and detection of minimal 
residual disease in t(8;21)-positive acute myeloid leukaemia. Oncogene 8, 983-988. 
Charrad, R. S., Li, Y., Delpech, B., Balitrand, N., Clay, D., Jasmin, C., Chomienne, C., and 
Smadja-Joffe, F. (1999). Ligation of the CD44 adhesion molecule reverses blockage of 
differentiation in human acute myeloid leukaemia. Nat Med 5, 669-676. 
Choi, K. (2002). The hemangioblast: a common progenitor of haematopoietic and endothelial 
cells. J Hematother Stem Cell Res 11, 91-101. 
Chuang, S. S., and Li, C. Y. (1997). Useful panel of antibodies for the classification of acute 
leukaemia by immunohistochemical methods in bone marrow trephine biopsy specimens. 
Am J Clin Pathol 107, 410-418. 
Collins, S. J., Robertson, K. A., and Mueller, L. (1990). Retinoic acid-induced granulocytic 
differentiation of HL-60 myeloid leukaemia cells is mediated directly through the retinoic acid 
receptor (RAR-alpha). Mol Cell Biol 10, 2154-2163. 
Coussens, L. M., Shapiro, S. D., Soloway, P. D., and Werb, Z. (2001). Models for gain-of-
function and loss-of-function of MMPs. Transgenic and gene targeted mice. Methods Mol 
Biol 151, 149-179. 
Cumano, A., Dieterlen-Lievre, F., and Godin, I. (1996). Lymphoid potential, probed before 
circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86, 907-916. 
Cumano, A., Furlonger, C., and Paige, C. J. (1993). Differentiation and characterization of B-
cell precursors detected in the yolk sac and embryo body of embryos beginning at the 10- to 
12-somite stage. Proc Natl Acad Sci U S A 90, 6429-6433. 
References 
85 
Davidson, A. J., and Zon, L. I. (2004). The 'definitive' (and 'primitive') guide to zebrafish 
haematopoiesis. Oncogene 23, 7233-7246. 
Dick, J. E. (2005). Acute myeloid leukaemia stem cells. Ann N Y Acad Sci 1044, 1-5. 
Dick, J. E., and Lapidot, T. (2005). Biology of normal and acute myeloid leukaemia stem cells. 
Int J Hematol 82, 389-396. 
Downing, J. R. (1999). The AML1-ETO chimaeric transcription factor in acute myeloid 
leukaemia: biology and clinical significance. Br J Haematol 106, 296-308. 
Durr, M., Harder, F., Merkel, A., Bug, G., Henschler, R., and Muller, A. M. (2003). 
Chimaerism and erythroid marker expression after microinjection of human acute myeloid 
leukaemia cells into murine blastocysts. Oncogene 22, 9185-9191. 
Dzierzak, E., and Medvinsky, A. (1995). Mouse embryonic haematopoiesis. Trends Genet 11, 
359-366. 
Dzierzak, E., Medvinsky, A., and de Bruijn, M. (1998). Qualitative and quantitative aspects of 
haematopoietic cell development in the mammalian embryo. Immunol Today 19, 228-236. 
Eaves CJ, E. A. (1999). Anatomy and physiology of haematopoiesis. In Childhood 
Leukaemias, P. CH, ed. (NY, Cambridge University Press), pp. 53-71. 
Ema, H., Kitano, K., Suda, T., Sato, Y., Muroi, K., Ohta, M., Yoshida, M., Sakamoto, S., 
Eguchi, M., and Miura, Y. (1990). In vitro differentiation of leukaemic cells to eosinophils in 
the presence of interleukin-5 in two cases of acute myeloid leukaemia with the translocation 
(8;21)(q22;q22). Blood 75, 350-356. 
Erickson, P., Gao, J., Chang, K. S., Look, T., Whisenant, E., Raimondi, S., Lasher, R., 
Trujillo, J., Rowley, J., and Drabkin, H. (1992). Identification of breakpoints in t(8;21) acute 
myelogenous leukaemia and isolation of a fusion transcript, AML1/ETO, with similarity to 
Drosophila segmentation gene, runt. Blood 80, 1825-1831. 
Erickson, P. F., Dessev, G., Lasher, R. S., Philips, G., Robinson, M., and Drabkin, H. A. 
(1996). ETO and AML1 phosphoproteins are expressed in CD34+ haematopoietic 
progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 
88, 1813-1823. 
References 
86 
Faust, N., Huber, M. C., Sippel, A. E., and Bonifer, C. (1997). Different macrophage 
populations develop from embryonic/foetal and adult haematopoietic tissues. Exp Hematol 
25, 432-444. 
Ferrero, D., Carlesso, N., Pregno, P., Gallo, E., and Pileri, A. (1992). Self-renewal inhibition 
of acute myeloid leukaemia clonogenic cells by biological inducers of differentiation. 
Leukaemia 6, 100-106. 
Fidler, I. J. (1990). Critical factors in the biology of human cancer metastasis: twenty-eighth 
G.H.A. Clowes memorial award lecture. Cancer Res 50, 6130-6138. 
Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G., and Lazar, M. A. (1998). 
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the 
acute myeloid leukaemia fusion partner ETO. Mol Cell Biol 18, 7185-7191. 
Gitig, D. M., and Koff, A. (2000). Cdk pathway: cyclin-dependent kinases and cyclin-
dependent kinase inhibitors. Methods Mol Biol 142, 109-123. 
Greenberg, P. L., Negrin, R., and Nagler, A. (1990). Effects of CSFs in preleukaemia. Bone 
Marrow Transplant 6 Suppl 1, 121-126. 
Greiner, A., Knorr, C., Qin, Y., Sebald, W., Schimpl, A., Banchereau, J., and Muller-
Hermelink, H. K. (1997). Low-grade B cell lymphomas of mucosa-associated lymphoid tissue 
(MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and 
differentiation. Am J Pathol 150, 1583-1593. 
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, 
I., Stevens, R., Burnett, A., and Goldstone, A. (1998). The importance of diagnostic 
cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 
trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 
92, 2322-2333. 
Harada, Y., Harada, H., Downing, J. R., and Kimura, A. (2001). A haematopoietic-specific 
transmembrane protein, Art-1, is possibly regulated by AML1. Biochem Biophys Res 
Commun 284, 714-722. 
Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993). The p21 Cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816. 
References 
87 
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., 
Lister, T. A., and Bloomfield, C. D. (1999). World Health Organization classification of 
neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical 
Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17, 3835-
3849. 
He, L. Z., Merghoub, T., and Pandolfi, P. P. (1999). In vivo analysis of the molecular 
pathogenesis of acute promyelocytic leukaemia in the mouse and its therapeutic implications. 
Oncogene 18, 5278-5292. 
Heidenreich, O., Krauter, J., Riehle, H., Hadwiger, P., John, M., Heil, G., Vornlocher, H. P., 
and Nordheim, A. (2003). AML1/MTG8 oncogene suppression by small interfering RNAs 
supports myeloid differentiation of t(8;21)-positive leukaemic cells. Blood 101, 3157-3163. 
Henschler, R., Gottig, S., Junghahn, I., Bug, G., Seifried, E., Muller, A. M., and Fichtner, I. 
(2005). Transplantation of human acute myeloid leukaemia (AML) cells in immunodeficient 
mice reveals altered cell surface phenotypes and expression of human endothelial markers. 
Leuk Res 29, 1191-1199. 
Hogge, D. E., Lansdorp, P. M., Reid, D., Gerhard, B., and Eaves, C. J. (1996). Enhanced 
detection, maintenance, and differentiation of primitive human haematopoietic cells in 
cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-
3, and granulocyte colony-stimulating factor. Blood 88, 3765-3773. 
Hope, K. J., Jin, L., and Dick, J. E. (2003). Human acute myeloid leukaemia stem cells. Arch 
Med Res 34, 507-514. 
Hope, K. J., Jin, L., and Dick, J. E. (2004). Acute myeloid leukaemia originates from a 
hierarchy of leukaemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5, 
738-743. 
Howell, A. L., Stukel, T. A., Bloomfield, C. D., Davey, F. R., and Ball, E. D. (1990). Induction 
of differentiation in blast cells and leukaemia colony-forming cells from patients with acute 
myeloid leukaemia. Blood 75, 721-729. 
Hozumi, M. (1998). Differentiation therapy of leukaemia: achievements, limitations and future 
prospects. Int J Hematol 68, 107-129. 
References 
88 
Hurley, R. W., McCarthy, J. B., and Verfaillie, C. M. (1995). Direct adhesion to bone marrow 
stroma via fibronectin receptors inhibits haematopoietic progenitor proliferation. J Clin Invest 
96, 511-519. 
Hwang, E. S., Hong, J. H., Bae, S. C., Ito, Y., and Lee, S. K. (1999). Regulation of c-fos gene 
transcription and myeloid cell differentiation by acute myeloid leukaemia 1 and acute myeloid 
leukaemia-MTG8, a chimeric leukemogenic derivative of acute myeloid leukaemia 1. FEBS 
Lett 446, 86-90. 
Ikeda, H., Kanakura, Y., Furitsu, T., Kitayama, H., Sugahara, H., Nishiura, T., Karasuno, T., 
Tomiyama, Y., Yamatodani, A., Kanayama, Y., and et al. (1993). Changes in phenotype and 
proliferative potential of human acute myeloblastic leukaemia cells in culture with stem cell 
factor. Exp Hematol 21, 1686-1694. 
Illmensee, K., and Mintz, B. (1976). Totipotency and normal differentiation of single 
teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci U S A 73, 549-
553. 
Ishiyama, T., Kano, J., Minami, Y., Iijima, T., Morishita, Y., and Noguchi, M. (2003). 
Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation 
of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and 
immortalized hepatocytes. Cancer Sci 94, 757-763. 
Jakubowiak, A., Pouponnot, C., Berguido, F., Frank, R., Mao, S., Massague, J., and Nimer, 
S. D. (2000). Inhibition of the transforming growth factor beta 1 signaling pathway by the 
AML1/ETO leukaemia-associated fusion protein. J Biol Chem 275, 40282-40287. 
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., and Dick, J. E. (2006). Targeting of CD44 
eradicates human acute myeloid leukaemic stem cells. Nat Med 12, 1167-1174. 
Jinnai, I. (1995). [Clonal study of haematopoietic cells]. Rinsho Ketsueki 36, 273-278. 
Kitabayashi, I., Ida, K., Morohoshi, F., Yokoyama, A., Mitsuhashi, N., Shimizu, K., Nomura, 
N., Hayashi, Y., and Ohki, M. (1998). The AML1-MTG8 leukaemic fusion protein forms a 
complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol 18, 
846-858. 
References 
89 
Koeffler, H. P., Bar-Eli, M., and Territo, M. C. (1981). Phorbol ester effect on differentiation of 
human myeloid leukaemia cell lines blocked at different stages of maturation. Cancer Res 41, 
919-926. 
Koepp, D. M., Harper, J. W., and Elledge, S. J. (1999). How the cyclin became a cyclin: 
regulated proteolysis in the cell cycle. Cell 97, 431-434. 
Koga, H., Harada, M., Ohtsubo, M., Shishido, S., Kumemura, H., Hanada, S., Taniguchi, E., 
Yamashita, K., Kumashiro, R., Ueno, T., and Sata, M. (2003). Troglitazone induces p27Kip1-
associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. 
Hepatology 37, 1086-1096. 
Kogan, S. C., and Bishop, J. M. (1999). Acute promyelocytic leukaemia: from treatment to 
genetics and back. Oncogene 18, 5261-5267. 
Kohzaki, H., Ito, K., Huang, G., Wee, H. J., Murakami, Y., and Ito, Y. (1999). Block of 
granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed 
Bcl-2. Oncogene 18, 4055-4062. 
Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A. Y., Afanasiev, B. V., and Andreeff, M. 
(2002). Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic 
proteins. Leukaemia 16, 1713-1724. 
Kreuzer, K. A., Lass, U., Landt, O., Nitsche, A., Laser, J., Ellerbrok, H., Pauli, G., Huhn, D., 
and Schmidt, C. A. (1999). Highly sensitive and specific fluorescence reverse transcription-
PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative 
reference. Clin Chem 45, 297-300. 
Kulesa, P. M., Kasemeier-Kulesa, J. C., Teddy, J. M., Margaryan, N. V., Seftor, E. A., Seftor, 
R. E., and Hendrix, M. J. (2006). Reprogramming metastatic melanoma cells to assume a 
neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci U S A 
103, 3752-3757. 
Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F., and Berger, R. 
(1991). NB4, a maturation inducible cell line with t(15;17) marker isolated from a human 
acute promyelocytic leukaemia (M3). Blood 77, 1080-1086. 
References 
90 
Leith, C. P., Chen, I. M., Kopecky, K. J., Appelbaum, F. R., Head, D. R., Godwin, J. E., 
Weick, J. K., and Willman, C. L. (1995). Correlation of multidrug resistance (MDR1) protein 
expression with functional dye/drug efflux in acute myeloid leukaemia by multiparameter flow 
cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 86, 
2329-2342. 
Licht, J. D. (2001). AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) 
AML. Oncogene 20, 5660-5679. 
Linggi, B., Muller-Tidow, C., van de Locht, L., Hu, M., Nip, J., Serve, H., Berdel, W. E., van 
der Reijden, B., Quelle, D. E., Rowley, J. D., et al. (2002). The t(8;21) fusion protein, AML1 
ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute 
myeloid leukaemia. Nat Med 8, 743-750. 
Liu, C. P., and Auerbach, R. (1991). Ontogeny of murine T cells: thymus-regulated 
development of T cell receptor-bearing cells derived from embryonic yolk sac. Eur J Immunol 
21, 1849-1855. 
Look, A. L. (1997). Oncogenic transcription factors in the human acute leukaemias. Science 
278, 1059-1064. 
Lowenberg, B., Downing, J. R., and Burnett, A. (1999). Acute myeloid leukaemia. N Engl J 
Med 341, 1051-1062. 
Lutterbach, B., Westendorf, J. J., Linggi, B., Patten, A., Moniwa, M., Davie, J. R., Huynh, K. 
D., Bardwell, V. J., Lavinsky, R. M., Rosenfeld, M. G., et al. (1998). ETO, a target of t(8;21) in 
acute leukaemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18, 7176-
7184. 
Lyons, A. B., and Parish, C. R. (1994). Determination of lymphocyte division by flow 
cytometry. J Immunol Methods 171, 131-137. 
Manfredini, R., Trevisan, F., Grande, A., Tagliafico, E., Montanari, M., Lemoli, R., Visani, G., 
Tura, S., and Ferrari, S. (1999). Induction of a functional vitamin D receptor in all-trans-
retinoic acid-induced monocytic differentiation of M2-type leukaemic blast cells. Cancer Res 
59, 3803-3811. 
References 
91 
Mao, S., Frank, R. C., Zhang, J., Miyazaki, Y., and Nimer, S. D. (1999). Functional and 
physical interactions between AML1 proteins and an ETS protein, MEF: implications for the 
pathogenesis of t(8;21)-positive leukaemias. Mol Cell Biol 19, 3635-3644. 
Masciulli, R., Testa, U., Barberi, T., Samoggia, P., Tritarelli, E., Pustorino, R., 
Mastroberardino, G., Camagna, A., and Peschle, C. (1995). Combined vitamin D3/retinoic 
acid induction of human promyelocytic cell lines: enhanced phagocytic cell maturation and 
hybrid granulomonocytic phenotype. Cell Growth Differ 6, 493-503. 
Matsushima, T., Saitoh, T., Karasawa, M., Takizawa, M., Miyawaki, S., Nojima, Y., and 
Murakami, H. (2001). Effect of cytokines on growth and differentiation of leukaemic cells with 
translocation t(6;9)(p23;q34). Br J Haematol 115, 812-816. 
Matsushime, H., Jinno, A., Takagi, N., and Shibuya, M. (1990). A novel mammalian protein 
kinase gene (mak) is highly expressed in testicular germ cells at and after meiosis. Mol Cell 
Biol 10, 2261-2268. 
Mayani, H. (1996). Composition and function of the hemopoietic microenvironment in human 
myeloid leukaemia. Leukaemia 10, 1041-1047. 
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. 
A., Moore, J. O., McIntyre, O. R., and Frei, E., 3rd (1994). Intensive postremission 
chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukaemia Group B. N 
Engl J Med 331, 896-903. 
Medvinsky, A., and Dzierzak, E. (1996). Definitive haematopoiesis is autonomously initiated 
by the AGM region. Cell 86, 897-906. 
Meyers, S., Downing, J. R., and Hiebert, S. W. (1993). Identification of AML-1 and the (8;21) 
translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt 
homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 
13, 6336-6345. 
Meyerson, M., and Harlow, E. (1994). Identification of G1 kinase activity for cdk6, a novel 
cyclin D partner. Mol Cell Biol 14, 2077-2086. 
References 
92 
Mikhail, F. M., Serry, K. A., Hatem, N., Mourad, Z. I., Farawela, H. M., El Kaffash, D. M., 
Coignet, L., and Nucifora, G. (2002). AML1 gene over-expression in childhood acute 
lymphoblastic leukaemia. Leukaemia 16, 658-668. 
Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., and 
Ohki, M. (1993). The t(8;21) translocation in acute myeloid leukaemia results in production of 
an AML1-MTG8 fusion transcript. Embo J 12, 2715-2721. 
Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., and Ohki, M. (1991). t(8;21) 
breakpoints on chromosome 21 in acute myeloid leukaemia are clustered within a limited 
region of a single gene, AML1. Proc Natl Acad Sci U S A 88, 10431-10434. 
Moore, K. A., Ema, H., and Lemischka, I. R. (1997). In vitro maintenance of highly purified, 
transplantable haematopoietic stem cells. Blood 89, 4337-4347. 
Morikawa, K., Walker, S. M., Nakajima, M., Pathak, S., Jessup, J. M., and Fidler, I. J. (1988). 
Influence of organ environment on the growth, selection, and metastasis of human colon 
carcinoma cells in nude mice. Cancer Res 48, 6863-6871. 
Motoji, T., Okada, M., Takanashi, M., Masuda, M., Tanaka, K., Oshimi, K., and Mizoguchi, H. 
(1990). Induction of eosinophilic colonies by interleukin-5 on acute myeloblastic leukaemic 
cells. Br J Haematol 74, 169-172. 
Motoji, T., Okada, M., Takanashi, M., Oshimi, K., and Mizoguchi, H. (1995). Abolition of 
suppressive effect of acute myeloid leukaemia cells on normal granulocyte-macrophage 
colony formation induced by interleukin-5 associated with eosinophilic cell induction. Leuk 
Lymphoma 18, 171-178. 
Mrozek, K., Prior, T. W., Edwards, C., Marcucci, G., Carroll, A. J., Snyder, P. J., Koduru, P. 
R., and al., e. (2001). Comparison of cytogenetic and molecular genetic detection of t(8;21) 
and inv(16) in a prospective series of adults with de novo acute myeloid leukaemia: a Cancer 
and Leukaemia Group B Study. J Clin Oncol 19, 2482-2492. 
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., 
Hiddemann, W., Ito, Y., and Tenen, D. G. (2002). Heterozygous PU.1 mutations are 
associated with acute myeloid leukaemia. Blood 100, 998-1007. 
References 
93 
Mueller, M. M., and Fusenig, N. E. (2004). Friends or foes - bipolar effects of the tumour 
stroma in cancer. Nat Rev Cancer 4, 839-849. 
Muller, A. M., Medvinsky, A., Strouboulis, J., Grosveld, F., and Dzierzak, E. (1994). 
Development of haematopoietic stem cell activity in the mouse embryo. Immunity 1, 291-301. 
Muller, R., Mumberg, D., and Lucibello, F. C. (1993). Signals and genes in the control of cell-
cycle progression. Biochim Biophys Acta 1155, 151-179. 
Mulloy, J. C., Cammenga, J., MacKenzie, K. L., Berguido, F. J., Moore, M. A., and Nimer, S. 
D. (2002). The AML1-ETO fusion protein promotes the expansion of human haematopoietic 
stem cells. Blood 99, 15-23. 
Nead, M. A., Baglia, L. A., Antinore, M. J., Ludlow, J. W., and McCance, D. J. (1998). Rb 
binds c-Jun and activates transcription. Embo J 17, 2342-2352. 
Nishitani, J., Nishinaka, T., Cheng, C. H., Rong, W., Yokoyama, K. K., and Chiu, R. (1999). 
Recruitment of the retinoblastoma protein to c-Jun enhances transcription activity mediated 
through the AP-1 binding site. J Biol Chem 274, 5454-5461. 
Nisson, P. E., Watkins, P. C., and Sacchi, N. (1992). Transcriptionally active chimeric gene 
derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) 
leukaemic cells. Cancer Genet Cytogenet 63, 81-88. 
Nucifora, G., Birn, D. J., Erickson, P., Gao, J., LeBeau, M. M., Drabkin, H. A., and Rowley, J. 
D. (1993). Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO 
fusion mRNA in patients with t(8;21) acute myeloid leukaemia. Blood 81, 883-888. 
Ogawa, M. (1993). Differentiation and Proliferation of Haematopoietic Stem Cells. Blood 81, 
2844-2853. 
Ogawa, M., Nishikawa, S., Ikuta, K., Yamamura, F., Naito, M., Takahashi, K., and Nishikawa, 
S.-I. (1988). B cell ontogeny in murine embryo studie by a culture system with the monolayer 
of a stromal cell clone, ST2: B cell progenotor develops first in embryonal body rather than in 
the yolk sac. EMBO 7, 1337-1343. 
References 
94 
Ohneda, O., Fennie, C., Zheng, Z., Donahue, C., La, H., Villacorta, R., Cairns, B., and Lasky, 
L. A. (1998). Haematopoietic stem cell maintenance and differentiation are supported by 
embryonic aorta-gonad-mesonephros region-derived endothelium. Blood 92, 908-919. 
Okuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C. J., van Deursen, J. M., Harada, H., and 
Downing, J. R. (1998). Expression of a knocked-in AML1-ETO leukaemia gene inhibits the 
establishment of normal definitive haematopoiesis and directly generates dysplastic 
haematopoietic progenitors. Blood 91, 3134-3143. 
Okuda, T., Nishimura, M., Nakao, M., and Fujita, Y. (2001). RUNX1/AML1: a central player in 
haematopoiesis. Int J Hematol 74, 252-257. 
Oostendorp, R. A., Harvey, K. N., Kusadasi, N., de Bruijn, M. F., Saris, C., Ploemacher, R. E., 
Medvinsky, A. L., and Dzierzak, E. A. (2002). Stromal cell lines from mouse aorta-gonads-
mesonephros subregions are potent supporters of haematopoietic stem cell activity. Blood 
99, 1183-1189. 
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, 
W., Zhang, D. E., and Tenen, D. G. (2001). AML1-ETO downregulates the granulocytic 
differentiation factor C/EBPalpha in t(8;21) myeloid leukaemia. Nat Med 7, 444-451. 
Petrovick, M. S., Hiebert, S. W., Friedman, A. D., Hetherington, C. J., Tenen, D. G., and 
Zhang, D. E. (1998). Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize 
with different regions of AML1. Mol Cell Biol 18, 3915-3925. 
Rhoades, K. L., Hetherington, C. J., Harakawa, N., Yergeau, D. A., Zhou, L., Liu, L. Q., Little, 
M. T., Tenen, D. G., and Zhang, D. E. (2000). Analysis of the role of AML1-ETO in 
leukemogenesis, using an inducible transgenic mouse model. Blood 96, 2108-2115. 
Rowe, J. M., Andersen, J. W., Mazza, J. J., Bennett, J. M., Paietta, E., Hayes, F. A., Oette, 
D., Cassileth, P. A., Stadtmauer, E. A., and Wiernik, P. H. (1995). A randomized placebo-
controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult 
patients (> 55 to 70 years of age) with acute myelogenous leukaemia: a study of the Eastern 
Cooperative Oncology Group (E1490). Blood 86, 457-462. 
Ruffner, K. L., and Matthews, D. C. (2000). Current uses of monoclonal antibodies in the 
treatment of acute leukaemia. Semin Oncol 27, 531-539. 
References 
95 
Sachs, L. (1978). Control of normal cell differentiation and the phenotypic reversion of 
malignancy in myeloid leukaemia. Nature 274, 535-539. 
Saito, H., Bourinbaiar, A., Ginsburg, M., Minato, K., Ceresi, E., Yamada, K., Machover, D., 
Breard, J., and Mathe, G. (1985). Establishment and characterization of a new human 
eosinophilic leukaemia cell line. Blood 66, 1233-1240. 
Salem, M., Delwel, R., Mahmoud, L. A., Clark, S., Elbasousy, E. M., and Lowenberg, B. 
(1989). Maturation of human acute myeloid leukaemia in vitro: the response to five 
recombinant haematopoietic factors in a serum-free system. Br J Haematol 71, 363-370. 
Santini, V., Colombat, P., Delwel, R., van Gurp, R., Touw, I., and Lowenberg, B. (1991). 
Induction of granulocytic maturation in acute myeloid leukaemia by G-CSF and retinoic acid. 
Leuk Res 15, 341-350. 
Sherr, C. J., and Roberts, J. M. (2004). Living with or without cyclins and cyclin-dependent 
kinases. Genes Dev 18, 2699-2711. 
Sievers, E. L. (2000). Clinical studies of new "biologic" approaches to therapy of acute 
myeloid leukaemia with monoclonal antibodies and immunoconjugates. Curr Opin Oncol 12, 
30-35. 
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., 
Shannon-Dorcy, K., Berger, M. S., and Bernstein, I. D. (1999). Selective ablation of acute 
myeloid leukaemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 
calicheamicin immunoconjugate. Blood 93, 3678-3684. 
Speck, N. A., Stacy, T., Wang, Q., North, T., Gu, T. L., Miller, J., Binder, M., and Marin-
Padilla, M. (1999). Core-binding factor: a central player in haematopoiesis and leukaemia. 
Cancer Res 59, 1789s-1793s. 
Steinman, R. A. (2002). Cell cycle regulators and haematopoiesis. Oncogene 21, 3403-3413. 
Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A., and el-Houseini, M. E. 
(1994). Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9, 3389-3396. 
References 
96 
Steinman, R. A., Huang, J., Yaroslavskiy, B., Goff, J. P., Ball, E. D., and Nguyen, A. (1998). 
Regulation of p21(WAF1) expression during normal myeloid differentiation. Blood 91, 4531-
4542. 
Sutherland H.J., E. A. C., Eaves C.J. (1991). Quantitative assays for human hemopoietic 
progenitor cells. In Bone Marrow Processing and Purging: A Practical 
Guide., G. AP., ed. (CRC Press Inc), pp. 155-171. 
Sutherland, H. J., Blair, A., and Zapf, R. W. (1996). Characterization of a hierarchy in human 
acute myeloid leukaemia progenitor cells. Blood 87, 4754-4761. 
Tallman, M. S. (1996). Differentiating therapy in acute myeloid leukaemia. Leukaemia 10, 
1262-1268. 
Tanaka, K., Tanaka, T., Kurokawa, M., Imai, Y., Ogawa, S., Mitani, K., Yazaki, Y., and Hirai, 
H. (1998). The AML1/ETO(MTG8) and AML1/Evi-1 leukaemia-associated chimeric 
oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type 
AML1. Blood 91, 1688-1699. 
Tanaka, T., Mitani, K., Kurokawa, M., Ogawa, S., Tanaka, K., Nishida, J., Yazaki, Y., Shibata, 
Y., and Hirai, H. (1995). Dual functions of the AML1/Evi-1 chimeric protein in the mechanism 
of leukemogenesis in t(3;21) leukaemias. Mol Cell Biol 15, 2383-2392. 
Taylor, P. R., Reid, M. M., Stark, A. N., Bown, N., Hamilton, P. J., and Proctor, S. J. (1995). 
De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of 
incidence, treatment and outcome. Northern Region Haematology Group. Leukaemia 9, 231-
237. 
Tenen, D. G., Hromas, R., Licht, J. D., and Zhang, D. E. (1997). Transcription factors, normal 
myeloid development, and leukaemia. Blood 90, 489-519. 
Timchenko, N. A., Wilde, M., Nakanishi, M., Smith, J. R., and Darlington, G. J. (1996). 
CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the 
p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 10, 804-815. 
Tlsty, T. D. (2001). Stromal cells can contribute oncogenic signals. Semin Cancer Biol 11, 
97-104. 
References 
97 
van den Hooff, A. (1988). Stromal involvement in malignant growth. Adv Cancer Res 50, 
159-196. 
Velardi, A., and Cooper, M. D. (1984). An immunofluorescence analysis of the ontogeny of 
myeloid, T, and B lineage cells in mouse hemopoietic tissues. J Immunol 133, 672-677. 
Walter, M. J., Park, J. S., Ries, R. E., Lau, S. K., McLellan, M., Jaeger, S., Wilson, R. K., 
Mardis, E. R., and Ley, T. J. (2005). Reduced PU.1 expression causes myeloid progenitor 
expansion and increased leukaemia penetrance in mice expressing PML-RARalpha. Proc 
Natl Acad Sci U S A 102, 12513-12518. 
Wang, H., Iakova, P., Wilde, M., Welm, A., Goode, T., Roesler, W. J., and Timchenko, N. A. 
(2001). C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol 
Cell 8, 817-828. 
Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S., and Liu, J. M. (1998). ETO, fusion partner 
in t(8;21) acute myeloid leukaemia, represses transcription by interaction with the human N-
CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 95, 10860-10865. 
Wang, J. H., Nichogiannopoulou, A., Wu, L., Sun, L., Sharpe, A. H., Bigby, M., and 
Georgopoulos, K. (1996). Selective defects in the development of the foetal and adult 
lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537-549. 
Watson, J. V., Chambers, S. H., and Smith, P. J. (1987). A pragmatic approach to the 
analysis of DNA histograms with a definable G1 peak. Cytometry 8, 1-8. 
Westendorf, J. J., Yamamoto, C. M., Lenny, N., Downing, J. R., Selsted, M. E., and Hiebert, 
S. W. (1998). The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits 
C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 
18, 322-333. 
Williams, R. L., Risau, W., Zerwes, H. G., Drexler, H., Aguzzi, A., and Wagner, E. F. (1989). 
Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by 
host cell recruitment. Cell 57, 1053-1063. 
Wills, R. A. (1967). The pathology of tumours (London, Butterworths ). 
References 
98 
Yergeau, D. A., Hetherington, C. J., Wang, Q., Zhang, P., Sharpe, A. H., Binder, M., Marin-
Padilla, M., Tenen, D. G., Speck, N. A., and Zhang, D. E. (1997). Embryonic lethality and 
impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat 
Genet 15, 303-306. 
Yoder, M. C., King, B., Hiatt, K., and Williams, D. A. (1995). Murine embryonic yolk sac cells 
promote in vitro proliferation of bone marrow high proliferative potential colony-forming cells. 
Blood 86, 1322-1330. 
Yoder, M. C., Papaioannou, V. E., Breitfeld, P. P., and Williams, D. A. (1994). Murine yolk 
sac endoderm- and mesoderm-derived cell lines support in vitro growth and differentiation of 
haematopoietic cells. Blood 83, 2436-2443. 
Yuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., 
Lagasse, E., Weissman, I. L., Akashi, K., and Zhang, D. E. (2001). AML1-ETO expression is 
directly involved in the development of acute myeloid leukaemia in the presence of additional 
mutations. Proc Natl Acad Sci U S A 98, 10398-10403. 
Zada, A. A., Singh, S. M., Reddy, V. A., Elsasser, A., Meisel, A., Haferlach, T., Tenen, D. G., 
Hiddemann, W., and Behre, G. (2003). Downregulation of c-Jun expression and cell cycle 
regulatory molecules in acute myeloid leukaemia cells upon CD44 ligation. Oncogene 22, 
2296-2308. 
Zhang, D. E., Hohaus, S., Voso, M. T., Chen, H. M., Smith, L. T., Hetherington, C. J., and 
Tenen, D. G. (1996). Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: 
regulation of multiple myeloid CSF receptor promoters. Curr Top Microbiol Immunol 211, 
137-147. 
 
 
 
 
 
 
 
 
 
Abbreviations 
 
99 
List of Abbreviations 
A adenine kb kilobases 
AGM aorta-gonad-mesonephros LIF leukaemia inhibitory factor 
ALL acute lymphocytic leukaemia Lin lineage 
AML acute myeloid leukaemia LSCs leukaemic stem cells 
ATRA all-trans retinoic acid LTC long term culture 
BCL-2 B-cell lymphoma-2 M molar 
BM bone marrow mAb monoclonal antibody 
BSA bovine serum albumin MC  methyl cellulose 
C bovine serum albumin MDS myelodysplastic syndrome 
CBF core binding factor min minutes 
CD cluster of differentiation ml mililitre 
cDNA complemetary DNA mM milimolar 
CFU-S colony-forming-unit of the spleen NCCs neural crest cells 
CML chronic myeloid leukaemia nd not done 
CMPs common myeloid preogenitors ng nanogram 
IL-3 interleukin 3 nm nanometer 
CR complete remission NOD/SCID non-obese diabetic/severe combined immunodeficient 
bp base pair ns not significant 
DAPI 4’, 6-diamidino-2-phenylindol PBS phosphate buffered saline 
DAS dorsal- aorta-stromal PCR polymerase chain reaction 
dATP deoxi-adenosine-triphosphate PE phycoerythrin 
dCTP deoxi-cytosine-triphosphate PFA paraformaldehyde 
dGTP deoxi-guanosine-triphosphate PI propidium iodide 
DMSO dimethylsulphoxide RCF relative centrifugal force 
DNA deoxiribonucleic acid RFS relapse free survival 
DNase deoxyribonuclease RNase ribonuclease 
dNTPs deoxi-nucleotide-triphosphates Rpm rounds per minute 
DSMZ 
Deutsche Sammlung von Mikro-
organismen und Zellkulturen 
GmbH 
RT room temperature 
dTTP deoxi-thymidine-triphosphate RT-PCR reverse transcription -PCR 
dUTP deoxi-uridine-triphosphate SDS sodium dodecyl sulphate 
E embryonic day sec second 
ECM extracellular matrix SMMHC smooth muscle myosin heavy chain 
EDTA ethylendiaminotetraacetic acid SV40LT Simian virus 40 large T antigen 
ETO eight-twenty-one T thymine 
EtOH eight-twenty-one t(8;21) translocation(8;21) 
FAB French-American-British TBE tris-borate-EDTA 
FACS fluorescence-activated cell sorter TGFβ transforming growth factor beta 
FCS foetal calf serum TWEEN20 polyoxyethylenesorbitan monolaurate 
FITC fluorescein-5-isothiocyanate U units 
G guanine V volt 
HDAC histone deacetylase WHO world health organization 
g gravitation: 9.81m/s2 YSE yolk sac endodermal 
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G-CSF granulocyte-colony stimulating factor YSM yolk sac mesodermal 
GM-
CSF 
granulocyte/macrophage-colony 
stimulating factor µg microgram 
HEPES N-2-hydroxyethylpiperazin-N’-2-ethansulphonacid µl microlitre 
HSCs haematopoietic stem cells µm micrometer 
IMDM Iscove’s modified Eagle’s medium   
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